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SUMMARY
The effects of a number of analogues of ADP and ATP were determined on increases in 
platelet cytosolic calcium concentration ([Ca2+]j). ADP, 2-methyIthio-ADP, adenosine 
5'-0-( 1 -thiodiphosphate) and adenosine 5’-0-(2-thiodiphosphate) each induced increases 
in [Ca2+]j in a manner similar to their reported ability to induce platelet aggregation. The 
effects of these compounds were antagonized by ATP (a selective ADP receptor 
antagonist) and in the case of ADP this antagonism was shown to be competitive by 
Schild analysis. 2-chloro-ATP, adenosine 5'-0-( 1 -thiotriphosphate), adenosine 
5’-0-(2-thiotriphosphate), P1,P5-diadenosine pentaphosphate and adenylyl 5’-(p,y- 
methylene)diphosphonate all inhibited ADP-induced increases in [Ca2+]; in an apparently 
competitive manner. The pA2 values obtained for these compounds and for ATP as 
inhibitors of increases in [Ca2+]; showed a good correlation with those obtained for these 
compounds as inhibitors of aggregation. Adenosine 5,-(a,p-methylene)triphosphonate and 
UTP were only weak inhibitors of ADP-induced increases in [Ca2+]; whilst 
2-methylthio-ATP non-competitively inhibited the effect of ADP on platelet [Ca2+]j and 
these results are also consistent with the effects of these compounds on aggregation. This 
strong correlation between the effects of analogues of adenine nucleotides on platelet 
aggregation and on increases in [Ca2+]f confirms the causal relationship between these 
two actions of ADP and shows that they are mediated by the same receptor.
The effects of suramin, an antagonist of P2X and P2Y receptors, were investigated on a 
number of platelet responses. In washed platelets suramin acted as an apparently 
competitive inhibitor of platelet aggregation causing parallel rightward shifts in the log 
concentration-response curve with no depression of the maximal response. However, the
2
slope of the Schild plot was around 2 suggesting that the effect of suramin was not simply 
competitive. The value of suramin was 4.62. Suramin was also able to inhibit 
non-competitively aggregation induced by U46619 and by 5-hydroxytryptamine (5-HT). 
Suramin inhibited ADP-induced increases in [Ca2+]j in a similar manner to aggregation 
giving a Schild plot slope of ~2 and a pA2  value of 4.63. Again suramin was also able to 
inhibit non-competitively increases in [Ca2+]j induced by 5-HT. Suramin also inhibited the 
effect of ADP on prostaglandin Ej (PGE^-stimulated adenylate cyclase, however, in this 
case the slope of the Schild plot was not significantly different from unity suggesting that 
the effect was competitive. The pA2  value of suramin was 5.09. Suramin was also able to 
inhibit the stimulation of adenylate cyclase by PGEr  These results show that suramin is 
an antagonist of the platelet ADP receptor, as it is of P2X and P2Y receptors, although it 
also has non-specific inhibitory effects.
The effect of varying the extracellular divalent cation concentration was determined on 
platelet responses to ADP. There was a small but significant leftward shift in the log 
concentration-response curve to ADP in the presence of EGTA compared to that in the 
presence of both calcium and magnesium. This leftward shift was no longer significant 
when the log concentration-response curves were plotted against ADP3' rather than 
against total ADP concentration. There was also a marked increase in the pA  ^value of 
ATP in the presence of EGTA compared to the presence of calcium and magnesium. 
However, when the pA^ value was determined for ATP4* there was no longer a significant 
difference in the pA2  under these different conditions. Similar results were obtained when 
the inhibition of PGE,-stimulated adenylate cyclase was compared in the presence of 
calcium and magnesium and in the presence of EGTA. These results suggest that, in 
common with other P2-purinoceptors, the platelet ADP receptor recognises the
uncomplexed forms of adenine nucleotides.
In studies on the effect of divalent cation concentration on ADP-induced inhibition of 
adenylate cyclase, ATP not only inhibited the effect of ADP but also appeared to enhance 
the accumulation of cAMP induced by PGEj. However, ATP was unable to induce an 
increase in adenylate cyclase activity in the absence of PGEj and apyrase also enhanced 
the accumulation of cAMP induced by PGEj. This suggests that the effect of ATP was in 
fact due to inhibition of the effect of endogenous ADP released by platelets during 
preparation and storage rather than a true stimulation of adenylate cyclase.
In binding studies, platelets showed both high and low affinity binding sites for 
[35S]-Sp-ATPaS. There were -9000 high affinity sites per platelet with a KD value of 
0.21 pM and -24,000 low affinity sites with a KD value of 32 pM. This binding was not 
displaced by selective ligands at adenosine, or 5-HT2 receptors and was not displaced 
by FSBA but was displaced by a number of competitive ADP receptor antagonists. The 
low affinity binding was not displaced by suramin. However, the ability of some of these 
ligands to displace bound ATPaS was not consistent with their effects in functional 
studies suggesting that neither of these binding sites is the ADP receptor.
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CHAPTER 1 
GENERAL INTRODUCTION
14
1.1 Structure and Function of Platelets
Platelets are small, anucleate cells derived from bone marrow megakaryocytes. Under 
normal circumstances they circulate freely in the blood showing no interaction with the 
surrounding vessel walls (Roth, 1992). If, however, the vessel is damaged, platelets 
adhere to the exposed subendothelium, via a specific interaction with collagen (Marcus & 
Safier, 1993; Roth, 1992; Siess, 1989). Fibrillar collagen is an extremely potent stimulus 
to platelets and causes them to release a number of soluble mediators, such as ADP 
(which is also released from cells when damaged), thromboxane (TXA2) and 
5-hydroxytryptamine (5-HT) (Hourani & Cusack, 1991; Siess, 1989). These substances 
act as a positive feedback system activating circulating platelets and causing them to 
adhere to the platelets already recruited to the developing thrombus. Other proteins 
released from activated platelets help to stabilize the platelet aggregate by strengthening 
interactions between the recruited platelets. Platelet aggregates also form a surface upon 
which the clotting cascade can be activated (Ehrman et al, 1978) resulting in the 
formation of thrombin which is another potent platelet activator and is also the enzyme 
which converts fibrinogen into fibrin, a process which further stabilizes the developing 
thrombus. Thus the exposure of the subendothelium in damaged blood vessels initiates a 
series of events which results in the formation of a tight platelet plug at the site of the 
injury which prevents further and potentially fatal blood loss from occurring. ADP is well 
known for participating in aggregation induced by a number of other agonists in vitro 
(Hourani & Cusack, 1991; Siess, 1989) and evidence is now accumulating which suggests 
that ADP also plays an important role in vivo during thrombogenesis (Cattaneo et ah, 
1991; Cattaneo et a l, 1992; Emms & Lewis, 1986; Hirata et al., 1993; Kim et al., 1992; 
McClure et al., 1988).
Resting platelets are discoid (lentiform) in shape and about 3 jum in diameter (a 
diagrammatic representation of a platelet is shown in figure 1.1). This shape is 
maintained by a circumferential ring of microtubules located just below the plasma 
membrane (Behnke, 1970). Disruption of this microtubule ring e.g. by chilling the 
platelets or treating them with colchicine results in the loss of the discoid morphology, 
the platelets becoming spherical (White & Krivit, 1967; White, 1968a). This change in 
platelet shape is also seen in the early stages of the response of platelets to various 
stimuli. Platelets also contain a dense cytoskeleton of actin filaments which undergoes 
extensive changes during platelet shape change.
Platelets contain few mitochondria, but possess many glycogen granules which act as a 
store of glucose which is used to supply the increased energy demand during platelet 
activation (Crawford & Scrutton, 1987). They also contain numerous cytoplasmic storage 
granules (White, 1987). These granules can be classified into three different types, dense 
granules, a-granules and lysosomes, depending on their appearance under the electron 
microscope, the nature of their contents and the time course of their release from the 
platelet during activation. Dense granules appear as electron dense bodies with a 
characteristic 'bull’s eye' appearance under the electron microscope (White, 1987). Their 
contents seem to be the most readily released by platelet stimuli (Akkerman et a l , 1982). 
These granules contain large quantities of the adenine nucleotides ADP and ATP and 
biogenic amines (predominantly 5-hydroxytryptamine in the case of human platelets) as 
well as inorganic phosphate and pyrophosphate in a macromolecular complex with 
calcium and magnesium (Fukami et a l , 1980; Martin et a l, 1974; Meyers et a l, 1982; 
Plescher et a l, 1971; Skaer et a l, 1974). Dense granules also contain smaller quantities
16
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Figure 1.1 A diagrammatic representation of a section through a human platelet showing 
the major structural features.
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of guanine nucleotides (Holmsen, 1985). Both ADP and 5-HT are platelet aggregating 
agents and thus constitute a positive feedback mechanism helping to recruit further 
platelets to a developing thrombus. Along with ATP these substances also have potent 
effects on the tone of the surrounding vascular smooth muscle, causing relaxation in the 
presence of endothelium or contraction if the muscle is exposed to these mediators 
directly (Vanhoutte, 1988). Alpha granules are protein storage granules which contain a 
wide variety of substances including adhesive proteins (e.g. Von Willebrand factor and 
thrombospondin), coagulation factors (e.g. factor V) and cell mitogens (e.g 
platelet-derived growth factor), as well as fibrinogen, an essential factor in platelet 
aggregation (for a recent review on a-granules see Harrison & Cramer, 1993). Lysosomes 
are morphologically indistinguishable from a-granules, however, they can be identified 
as a distinct subset of these granules using cytochemical staining techniques (Bentfield & 
Bainton, 1975). Lysosomal acid hydrolases are only releasable by very strong platelet 
stimuli such as high concentrations of thrombin or collagen and are not released upon 
stimulation with ADP (Kaplan et a l, 1979). Indeed, platelet agonists can be classified by 
their abilities to induce the release of platelet granule contents: weak agonists (e.g. 5-HT 
& ADP) do not cause the release of granule contents at physiological calcium 
concentrations; intermediate agonists (TXA^ vasopressin & platelet-activating factor) 
induce the release of dense and a-granule contents but not those of lysosomes; strong 
platelet agonists (thrombin & collagen) can induce the release of all three classes of 
secretory granules although lysosomal contents are only released at high concentrations 
(Siess, 1989).
Platelets contain two closely associated membrane systems, the dense tubular system and
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the open canalicular system. The dense tubular system is wholly cytoplasmic and is 
derived from the endoplasmic reticulum of the parent megakaryocyte (White, 1987). It is 
probably the site within the platelet of the agonist-sensitive calcium store (Skaer et al., 
1974) and possesses an active uptake system (Ca2+-ATPase) which allows it to 
accumulate calcium from the cytoplasm, a process which is important in the maintenance 
of the resting cytosolic calcium concentration (Cutler et al.  ^ 1978; Kaser-Glanzmann et 
al., 1977). The open canalicular system is formed from extensive invaginations of the 
platelet plasma membrane and appears to come into close association with elements of 
the dense tubular system (White, 1972). It is thought to act as a conduit for the contents 
of the cytoplasmic granules when they are released (White, 1973). During platelet 
activation the cytoplasmic granules are concentrated at the centre of the cell due to a 
constriction of the circumferential microtubule ring (White, 1968b). The storage granules 
then discharge their contents into the extracellular medium by fusing with elements of the 
open canalicular system (White, 1973; 1974a). In common with the dense tubular system 
the open canalicular system also possesses a Ca2+-ATPase activity which participates in 
the maintenance and restoration of the resting cytoplasmic calcium concentration by 
extruding calcium across the plasma membrane into the extracellular medium (Cutler et 
al, 1978; Rink & Sage, 1987).
1.2 Purinoceptors
Extracellular adenosine and adenine nucleotides are known to have biological effects on 
a wide range of tissues via specific cell surface receptors known as purinoceptors. 
Purinoceptors were initially subclassified as P} and P2 purinoceptors which respond to 
either adenosine (P^ or ADP and ATP (P2), AMP has little if any activity at either
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subclass of purinoceptor. The effects of adenosine at Pj-purinoceptors were antagonized 
by substituted xanthines (e.g. caffeine and theophylline) whilst these compounds had no 
effect at P2-purinoceptors (see Bumstock, 1978).
The Pj purinoceptors have now been further subclassified into A, and A^  receptors. At Aj 
receptors the N6-substituted adenosine analogue N6-cyclopentyladenosine (CPA), is more 
potent than the 5’ substituted analogue 5'-N-ethylcarboxamidoadenosine (NECA), whilst 
at A2  receptors NECA is more potent than CPA. There are also a number of competitive 
antagonists of adenosine receptors which show very high selectivity for Aj over 
receptors (e.g. 8-cyclopentyl-l,3-dipropylxanthine), although there are as yet no highly 
selective \  antagonists. A x receptors occur presynaptically on neurones where they 
inhibit neurotransmitter release and occur on certain types of smooth muscle where they 
cause contraction (Bumstock, 1989). A2  receptors also occur on various types of smooth 
muscle and this class of adenosine receptor also occurs on platelets. In both cases these 
receptors are inhibitory causing relaxation of smooth muscle or preventing platelet 
aggregation by stimulating adenylate cyclase (Bumstock, 1989; Hourani & Cusack,
1991). There is now evidence that A2  receptors can be further subclassified into A^ and 
A^ receptors (Bruns, 1986). The platelet A^ receptor seems to be of the A^ subclass 
(Dionisotti et al., 1992). Molecular biological studies suggest that a novel third subclass 
of adenosine receptor (A3) also exists (Zhou et a l , 1992). Unlike other Pj receptors this 
A3 receptor appears to be insensitive to antagonism by substituted xanthines (Zhou et a l ,
1992). For a recent review of adenosine receptor classification see Collis & Hourani 
(1993).
The P2 purinoceptors have been subclassified into at least 5 subclasses, P2X, P2Y, P2Z, P2U
20
and P2T on the basis of structure activity relationships of these receptors for various 
adenine nucleotide analogues (Bumstock & Kennedy, 1985; Gordon, 1986; O'Connor et 
al, 1991). Some of these receptors have now been cloned (Lustig et al., 1993; Webb et 
al, 1993). There are, however, no selective, competitive antagonists for the subtypes of 
P2 receptor at present which hampers the production of a definitive system of 
sub-classification. A large number of ATP analogues have been synthesized and tested for 
their effects at these various receptor subtypes (Cusack & Hourani, 1990). However, 
classification of these receptors can be achieved by using only a small number of these 
analogues, namely the methylenephosphonate derivatives adenosine 5'-(a,p-methylene)- 
triphosphonate (AMPCPP) and adenylyl 5'-(P,y-methylene)diphosphonate (AMPPCP), 
the 2-substituted analogue 2-methylthioadenosine 5-triphosphate (MeSATP) and in the 
case of the more recently proposed subtypes the pyrimidine nucleotide uridine 
5-triphosphate (UTP). The P2X receptor is excitatory and occurs on various smooth 
muscles and sensory neurones (Gordon, 1986). At this receptor AMPCPP and AMPPCP 
are more potent than the parent nucleotide, ATP, which is equipotent with MeSATP 
(Bumstock & Kennedy, 1985). This structure activity relationship is effectively reversed 
at P2Y receptors where MeSATP is more potent than ATP whilst the 
methylenephosphonate analogues are less potent as agonists at this receptor subtype 
(Bumstock & Kennedy, 1985). P2Y receptors are generally inhibitory and occur on a wide 
variety of cell types including smooth muscle, endothelial cells and hepatocytes (Gordon, 
1986). The P2U receptor has the structure activity relationship UTP « ATP > MeSATP and 
shows similar functional effects to the P2Y receptor (O'Connor et a l, 1991). The P2Z 
receptor is found on a number of immune cells, e.g. mast cells, and mediates an 
ATP-induced cell permeabilization (Gordon, 1986). The agonist at the P2Z receptor seems
21
to be the tetrabasic form of ATP, ATP4-, rather than the divalent cation complex 
(MgATP2- & CaATP2-) which is the predominant form in physiological solutions 
(Cockcroft & Gomperts, 1979). Methylenephosphonate analogues of ATP are virtually 
inactive at this receptor, whilst MeSATP is approximately equipotent (Tatham et al., 
1988). Unlike the P2X and P2Y receptors at which ADP is approximately equipotent with 
ATP as an agonist, ADP has no activity at P^ receptors. The P2T receptor is found only on 
platelets (and megakaryocytes) where it mediates aggregation. The natural agonist for this 
receptor is ADP, ATP acting at this receptor as a competitive antagonist (Macfarlane & 
Mills, 1975). The stracture-activity relationships of the P2T receptor will be discussed in 
section 1.6.
1.3 Metabolism of Extracellular Adenine Nucleotides by Platelets
All tissues which have so far been studied possess enzymes which can metabolize 
extracellular adenine nucleotides (Meghji, 1993; Olsson & Pearson, 1990). In most 
tissues ATP and ADP are degraded by sequential dephosphorylation by 
'ecto-nucleotidase' enzymes to yield adenosine (Meghji, 1993; Olsson & Pearson, 1990). 
This adenosine can then be taken up by the tissue (where it can undergo further 
modification by cytoplasmic enzymes) or can be further degraded to inosine by 
extracellular adenosine deaminase (Meghji, 1993). Plasma also possesses enzyme 
activities capable of sequentially dephosphoiylating these nucleotides (Chambers et al., 
1968). However, although platelets have been reported to possess an 'ecto-ATPase' 
activity (Chambers et al., 1968), the major enzyme activity associated with the platelet 
surface appears to be nucleoside diphosphokinase (NDPK), which converts ADP to ATP 
without the concomitant formation of AMP, (Guccione et al, 1971; Packham et al.,
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1974). The previously reported ATPase activity may therefore be a consequence of the 
NDPK using the added ATP as a ’high-energy phosphate’ donor. This is also consistent 
with the observed enhancement of platelet NDPK activity in the presence of exogenously 
added ATP (Lips et ah, 1980).
1.4 Platelet Responses to ADP
1.4.1 Morphological Responses
For recent reviews of platelet activation by ADP see Siess, 1989; Gachet & Cazenave, 
1991; Hourani & Cusack, 1991. The initial observable response of platelets in suspension 
on stimulation with ADP is a change in shape from discoid to spherical with the 
extension of pseudopodia (Behnke, 1970; White, 1974b). During shape change the 
cytoplasmic granules are concentrated in the centre of the cell within a ’web-like' mesh of 
microtubules (White, 1968b). This mesh of microtubules seems to be formed by the 
translocation of the marginal bundle of microtubules from periphery of the cell towards 
the centre (White, 1968b). Shape change is also accompanied by marked changes in the 
arrangement of actin in the platelet cytoskeleton which, in activated platelets, forms long 
filaments extending from the centre of the cell into the pseudopodia whilst forming a 
mesh throughout the rest of the cell (Hartwig, 1992; Nachmias, 1980; White, 1984). 
There is also a decrease in the amount of G-actin within the platelet during shape change 
(Spangenberg et ah, 1992) suggesting an increase in the total amount of filamentous actin 
within the activated platelet as well as the change in its organization. Indeed, it has been 
suggested that actin polymerization may be the driving force for pseudopodium extension 
during shape change (Cohen et ah, 1978).
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Following shape change, if the concentration of ADP is sufficient, the platelets begin to 
aggregate. Pseudopodium formation during shape change seems to be important in this 
process (possibly by increasing the likelihood of contact between platelets) as shape 
changed platelets have been reported to be preferentially included into platelet aggregates 
(Milton & Frojmovic, 1984). Also the presence of low concentrations of cytochalasin B, 
which inhibits platelet shape change, reduces the rate of primary aggregation induced by 
ADP in citrated plasma (White, 1971) supporting this suggestion. This aggregation is 
reversible and dependent upon the presence of fibrinogen and at least micromolar levels 
of extracellular calcium (Solum & Stormorken, 1965; Zucker & Zaccardi, 1964). 
Exposure of platelets to ADP results in the exposure of fibrinogen binding sites on the 
platelet surface (Bennett & Vilaire, 1979; Marguerie et a l, 1979; Mustard et al., 1978; 
Peerschke et al., 1980). These binding sites appear to be located in the glycoprotein 
nb-ffla (Gp Ilb-EIa) complex since the platelets of patients with the inherited bleeding 
disorder Glanzmann’s thrombasthenia lack glycoproteins lib and Ilia (Phillips & Agin, 
1977) and fail to aggregate or to express fibrinogen binding sites in response to ADP 
(Bennett Sc Vilaire, 1979; Lee et al., 1981; Mustard et al., 1979) or indeed to a number of 
other agonists (George Sc Nurden, 1987; Hardistry Sc Caen, 1987; Siess, 1989). A 
Ca2+-dependent fibrinogen binding site has also been demonstrated in the complex 
formed from isolated glycoproteins Hb and Ilia (Nachman Sc Leung, 1982). Fibrinogen is 
a symmetrical molecule and is thought to mediate aggregation by forming cross-bridges 
between adjacent platelets via these binding sites. Fibrinogen can be immunolocalized 
between platelets in sections of ADP-induced platelet aggregates (Hensler et al., 1992; 
Suzuki et al., 1988). Also a recent study has shown that fibrinogen exhibits a bell-shaped 
dose-response relationship for aggregation with the peak of the aggregation curve
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occurring around the KD of fibrinogen for the fibrinogen receptor determined in parallel 
binding studies (Landolfi et a l, 1991). This suggests that fibrinogen supports optimal 
aggregation at a concentration which would provide one fibrinogen molecule for every 
two fibrinogen receptors, which is consistent with its suggested 'bridge-forming’ role.
In the presence of physiological concentrations of extracellular calcium (~1 mM) 
platelets undergo only a single, reversible phase of aggregation which is usually referred 
to as primary aggregation. However, under conditions where the extracellular calcium 
concentration is artificially reduced, for example in plasma anticoagulated with citrate, 
ADP causes the platelets to undergo two phases of aggregation. Primary aggregation 
occurs as described above, although this response appears to be weaker than that induced 
at more physiological calcium concentrations (Packham et al., 1989). Primary 
aggregation is then followed by a second and irreversible phase of aggregation 
(MacMillan, 1966). This secondary aggregation is associated with the production of 
prostaglandin endoperoxides and TXA2 and the release of platelet dense and a-granule 
contents. The irreversibility of secondary aggregation is thought to be due to 
thrombospondin released from the platelet a-granules binding to and stabilising the 
inter-platelet fibrinogen bridges (Lawler, 1986). Secondary aggregation and the release of 
granule contents are inhibited by cyclo-oxygenase inhibitors (Charo et a l, 1977; Mustard 
et a l, 1975) suggesting that thromboxane production occurs prior to release and that it is 
the thromboxane acting at its own cell surface receptor which causes release and thus 
renders aggregation irreversible. Unstirred platelets or platelets whose fibrinogen 
receptors have been blocked with a monoclonal antibody to Gp Hb-IIIa show severely 
impaired thromboxane production and do not release their granule contents (Balduini et
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a l , 1988). However, ADP-stimulated platelets do release their granule contents when 
they are brought into close contact by centrifugation (Massini & Liischer, 1971) 
suggesting that it is contact between platelets which acts as the stimulus for thromboxane 
production under conditions of reduced extracellular calcium concentration. It is not yet 
clear how platelet-platelet contact causes arachidonate release in the presence of reduced 
extracellular calcium. It should be noted that in the effective absence of calcium, e.g. in 
plasma anticoagulated with EDTA, platelets do not aggregate as micromolar 
concentrations of calcium are required for the association of glycoproteins lib and Ilia 
(Peerschke, 1985). Thus in the absence of calcium the fibrinogen receptor cannot form as 
the Gp Ilb-IIIa complex cannot form. Platelets do change shape under these conditions, 
however, suggesting that extracellular divalent cations are not essential for the binding of 
ADP to its receptor or for its agonist action.
1.4.2 Biochemical Responses
Biochemically, platelet activation induced by ADP can be correlated with three events: an 
increase in the cytosolic calcium concentration ([Ca2+];), inhibition of stimulated 
adenylate cyclase activity and the stimulation of Na+/H+-exchange. Na+/H+-exchange does 
not seem to be an important event in the induction of primary aggregation as primary 
aggregation to ADP is not altered in Na+-free medium (where Na+ was replaced 
iso-osmotically with N-methyl-D-glucosamine) or in the presence of concentrations of the 
drug amiloride (or its analogues) which are selective for the inhibition of 
Na+/H+-exchange (Connolly & Limbird, 1983; Funder et a l , 1988; Sweatt et a l , 1985). 
Na+/H+-exchange is important for secondary aggregation, however, as this phase of 
ADP-induced aggregation is absent under the above conditions. These and other studies
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suggest that Na+/H+-exchange is necessary for the activation of phospholipase A2 and the 
subsequent release of arachidonate metabolites which are required for platelet secondary 
aggregation (Funder et al., 1988; Siffert et al., 1990; Sweatt et al., 1985; Sweatt et al., 
1986a,b).
Agents which raise platelet cAMP levels (e.g. prostaglandins \  and EL and adenosine) are 
well known as inhibitors of platelet function (see for example Hourani & Cusack, 1991). 
ADP inhibits this stimulated adenylate cyclase activity (Cole et al., 1971; Haslam, 1973) 
presumably via a G; dependent mechanism (Aktories & Jakobs, 1985). This inhibitoiy 
activity of ADP is, however, not sufficient in itself to explain its ability to induce platelet 
aggregation since agents which selectively inhibit adenylate cyclase, such as 
2',5’-dideoxyadenosine or 9-(tetrahydro-2-furyl)-adenine (SQ22536), do not induce 
platelet aggregation and do not potentiate aggregation induced by aggregating agents 
when adenylate cyclase activity is not stimulated above basal (Haslam et al., 1978). Also 
some agonists, such as vasopressin, cause aggregation without inhibiting adenylate 
cyclase activity, although this does make its effects far more susceptible to inhibition by 
PGEj than those of ADP (Haslam et al., 1978). This ability of ADP to inhibit stimulated 
adenylate cyclase activity will, however, act to reduce the effects of inhibitory platelet 
agonists which may be present in the physiological situation and may play a role in the 
balancing of the response of platelets to the pro- and anti-aggregatory signals to which 
they are exposed within the circulation.
The response of platelets which is thought to initiate aggregation directly is an increase in 
platelet [Ca2+];. It remains unclear, however, how this increase in [Ca2+]j is elicited. ThereV
is good evidence that ADP can induce both influx of calcium across the plasma
27
membrane and release of calcium into the cytoplasm from intracellular stores and this 
will be discussed later in this section. However, only a few groups have looked at the 
effect of ADP on human platelet inositol lipid metabolism or inositol trisphosphate 
formation, which would be the prime candidate for the second messenger which 
mobilized calcium from intracellular stores, and there is some confusion as to its effects. 
Daniel et a l (1986) showed a significant (~2 fold) increase in the level of inositol 
1,4,5-trisphosphate in 32P-labelled, aspirinated, fura-2-loaded human platelets upon 
stimulation with ADP. Also Heemskerk et al (1993) have shown a transient increase in 
the level of inositol trisphosphate induced by ADP in washed aspirinated-platelets 
resuspended in a buffer containing lithium, apyrase and a physiological concentration of 
extracellular calcium. However, a number of other authors detect no such changes. Fisher 
et al (1985) showed no significant changes in the levels of phosphoinositides, 
phosphatidic acid or inositol phosphates in [3H]-inositol labelled, aspirinated platelets and 
Sweatt et a l (1986a) showed that indomethacin significantly reduced (>90%) inositol 
trisphosphate accumulation in platelets stimulated with ADP, although it did not 
completely abolish this effect. Also MacIntyre et al (1985) showed that whilst ADP was 
able to induce marked increases in platelet intracellular calcium concentration as 
measured in quin-2-loaded platelets, it did not induce a measurable increase in the levels 
of [32P]-phosphatidic acid in [32P]-phosphate-loaded platelets. This was in contrast to 
other calcium mobilizing agonists tested in this study. In a recent extensive study Vickers 
et a l (1990) showed that, in the presence of fibrinogen and a physiological concentration 
of extracellular calcium, ADP did not cause a significant increase in the level of inositol 
trisphosphate present in washed platelets. However, these authors did observe a slight but 
significant decrease in the amount of phosphatidylinositol mono- and bis-phosphates
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under the same conditions. Raha et al (1993) reported that ADP was able to induce 
transient increases in inositol trisphosphate levels during the first 4 sec of ADP 
stimulation using quenched flow techniques. However, shear forces in the experimental 
system were able to induce increases in inositol trisphosphate of similar magnitude and 
duration in control platelets making the significance of these results difficult to interpret. 
Using a more indirect approach Packham et al (1993) have suggested that phospholipase 
C does not play an important role in aggregation induced by ADP. These authors showed 
that in comparison with thrombin, an agonist which is known to activate phospholipase 
C, ADP-induced aggregation was insensitive to the effects of inhibition of diacylglycerol 
kinase (which should potentiate aggregation by prolonging the effect of endogenously 
released diacylglycerol) or to inhibition of protein kinase C by staurosporine both of 
which suggest that this arm of the PI pathway is only poorly activated by ADP. Thus 
activation of phospholipase C by ADP in human platelets seems to be a rather variable 
effect and would seem to play a relatively minor role in the response to this agonist.
In contrast to the confusion over the effects of ADP on platelet phosphoinositide 
metabolism, calcium mobilization induced by ADP presents a more coherent picture, 
although again this phenomenon shows some interesting differences from calcium 
mobilization induced by other aggregating agents. It has been known for some time that 
substances, including ADP, which can cause an increase in platelet [Ca2+]i do so in part 
by inducing influx of calcium across the plasma membrane from the extracellular 
medium. For example, when calcium mobilization is measured in the presence of 
divalent cation chelators (EGTA) to remove extracellular calcium, the increase in [Ca2+]; 
is reduced compared to that in the presence of extracellular calcium (Hallam & Rink, 
1985a). Of course, the fact that ADP is still able to cause an increase in [Ca2+]i in the
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absence of extracellular calcium does suggest that it is also able to mobilize calcium from 
the platelet's intracellular stores. Also, if quin-2-loaded platelets are stimulated in the 
presence of extracellular Mn2+, which quenches the fluorescence of calcium indicators 
such as quin-2 (Hesketh et a l, 1983), the intracellular dye signal shows rapid quenching 
suggesting the opening of divalent cation channels in the plasma membrane (Hallam & 
Rink, 1985b). However, when the sub-second kinetics of calcium mobilization induced 
by ADP or other aggregating agents were studied using stopped flow techniques (Sage & 
Rink, 1986; 1987; Sage et al., 1989) ADP was shown to cause its increase in [Ca2+]j much 
more rapidly than other agonists. In these studies maximally active concentrations of 
ADP were able to induce an increase in [Ca2+]; without a measurable delay (<10 ms) in 
the presence of extracellular calcium whilst with other agonists this response was always 
delayed by at least 200 ms. When these authors measured the kinetics of calcium 
mobilization in the absence of extracellular calcium or in the presence of Ni2+ (which 
blocks stimulated divalent cation influx across the plasma membrane, Hallam & Rink, 
1985b) the response to ADP was also delayed by -200 ms, showing that extracellular 
calcium is required for this rapid response to ADP. Interestingly, whilst the release of 
calcium from intracellular stores by ADP (i.e. that component of the increase which was 
present in the absence of extracellular calcium) was blocked by increased levels of 
cAMP, the influx of calcium across the plasma membrane was not. The increase in 
[Ca2+]; induced by thrombin was inhibited by cAMP in a similar manner in both the 
presence and absence of extracellular calcium. In the absence of extracellular calcium the 
effect of cAMP on ADP-induced and thrombin-induced calcium mobilization was very 
similar suggesting that this aspect of ADP-induced calcium mobilization may occur by a 
similar mechanism to that of aggregating agents known to stimulate phospholipase C.
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More recently Sage et al (1990) have shown that at 17°C calcium mobilization by ADP 
can be resolved into two distinct phases: a rapid phase which is dependent on the 
presence of extracellular calcium and which occurs without measurable delay, even at 
this reduced temperature, and a second phase delayed by -1.4 seconds at 17°C (and by 
about 200 ms at 37°C). From the rapid onset of the response and its insensitivity to 
changes in temperature it was suggested that the initial phase of calcium influx was due 
to the opening of a plasma membrane ion-channel closely coupled to the ADP receptor. 
Mahaut-Smith et al (1990; 1992) have now demonstrated the presence of ADP-gated 
cation channels in the platelet plasma membrane using patch clamping techniques both 
on isolated membrane patches and in whole cells. The delaying of the second phase of the 
transient, however, is consistent with the need to produce some form of diffusible second 
messenger. Interestingly, the release of calcium from intracellular stores (delayed phase) 
occurred with a shorter delay in the presence of extracellular calcium than in its absence 
(an observation which is also true of thrombin, Sage et a l , 1989) suggesting that 
extracellular calcium may by some mechanism modulate the release from intracellular 
stores. There is now some evidence that store-regulated calcium influx may involve 
tyrosine phosphorylation, as ADP (and thrombin) evoked calcium influx, but not 
mobilization of calcium from intracellular stores, has recently been shown to be inhibited 
by the tyrosine kinase inhibitors genistein and methyl-2,5-hydroxycinnamate, but not by 
an inactive analogue of genistein (Sargeant et a l , 1993a, b).
It should also be pointed out that in the above studies at 17°C, ADP also induced a 
biphasic influx of Mn2+ across the plasma membrane one phase of which occurred 
without measurable delay and is presumably due to the activation of the ADP-gated 
cation channel. The other, however, had similar kinetics to the phase of calcium
31
mobilization associated with store release and was blocked by increased cellular levels of 
cAMP. This was suggested to represent a mechanism by which intracellular calcium 
stores are refilled from the extracellular medium without the ion entering the cytosol and 
which may be controlled by the state of filling of the intracellular stores. This entry 
process appears to involve cytochrome-P450 as it is blocked by a number of agents which 
are said to inhibit microsomal cytochrome-P450 activity selectively, e.g. the imidazole 
antimycotic econazole, (Alonso et a l, 1991; Sargeant et a l, 1992).
Fluorescence microscopic studies on single fura-2-loaded platelets have revealed that 
ADP (and, indeed, thrombin) induced oscillating increases in intracellular calcium 
concentration (Heemskerk et a l , 1992, 1993; Nishio et al., 1992) in common with a 
number of other systems (e.g. Wakui et a l , 1990) and it has been suggested that these 
oscillations are mediated by a calcium-induced calcium release mechanism (Heemskerk 
et a l, 1993). However, platelets do not appear to contain the caffeine sensitive calcium 
storage pool which is thought to be involved in calcium oscillation and calcium-induced 
calcium release in other cell types (Foskett et a l, 1991a, b; Heemskerk et a l, 1993; 
Wakui et a l, 1990) and it has been suggested that a thapsigargin (a Ca2+-ATPase 
inhibitor) sensitive calcium store may assume this function in its stead. (Heemskerk et a l, 
1993). The current model concerning the mechanisms by which ADP induces an increase 
in [Ca2+]j are summarized in figure 1.2.
Associated with the activation of platelets by physiological agonists is the 
phosphorylation of two proteins, one of 20 kDa and one of 47 kDa (Siess, 1989). The 20 
kDa protein appears to be identical with the 20 kDa light chain of myosin (Daniel et a l, 
1981). The phosphorylation of myosin light chain is performed by a platelet
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Figure 1.2 A summary of the major processes thought to be associated with calcium 
mobilization induced by the ADP receptor. Abbreviations: R - the ADP receptor; AC - 
adenylate cyclase; Thaps - thapsigargin.
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Ca2Vcalmodulin-dependent myosin light chain kinase (Dabrowska & Hartshome, 1978; 
Hathaway & Adelstein, 1979) and is the major phosphorylation event associated with an 
increase in [Ca2+];. Phosphorylation of myosin light chain causes myosin to associate with 
cytoskeletal structures via an association with actin filaments (Fox & Phillips, 1982) and 
stimulates ATP-dependent contractile activity in platelet actomyosin complexes 
(Lebowitz & Cooke, 1978). Myosin phosphorylation has been suggested to be involved in 
the initiation (but not maintenance) of platelet shape change as ADP has been shown to 
induce the transient phosphorylation of myosin light chain with a similar time course to 
shape change (Daniel et al., 1984). This phosphorylation was not inhibited by 
indomethacin indicating that it was not due to released thromboxane but was inhibited by 
ATP, a competitive ADP antagonist (see later) indicating that the effect was directly 
mediated by the ADP receptor. Haslam & Lynham (1977) reported that ADP did not 
induce myosin phosphorylation, however, closer inspection of this paper suggests that 
this may be because the phosphorylation was measured at a time when it was later shown 
by Daniel et al. (1984) to have returned to control levels. The platelet 47 kDa protein 
appears to be the major substrate for protein kinase C (Siess, 1989), although its precise 
function is unknown. ADP has not consistently been reported to induce 47 kDa protein 
phosphorylation (Carty et a l, 1987; Daniel et al., 1984; Packham et a l, 1993) and in the 
study by Carty et al., who showed phosphorylation, the effect of ADP was sensitive to 
indomethacin suggesting an effect of released prostanoids. This lack of ADP-induced 47 
kDa protein phosphorylation again suggests that ADP has little or no effect on platelet 
phospholipase C activity.
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1.5 Measurement of Platelet Responses
Possibly the simplest method of measuring platelet activation is platelet aggregometiy, a 
method invented by Bom (1962a,b). In this method a beam of light is passed through a 
warmed, stirred sample of platelet suspension and the change in light transmission 
through the sample, relative to a platelet-free control, is measured. Shape change is seen 
as an initial small decrease in light transmission (increase in turbidity) accompanied by a 
decrease in the level of noise on the trace (due to the more homogeneous light scattering 
properties of spherical rather than discoid particles). Aggregation is then seen as an 
increase in light transmittance as the effective number of light scattering particles in the 
suspension decreases. This method may be used to measure aggregation) in I either 
platelet-rich plasma or of platelets suspended in buffer (washed platelets) in which case 
the addition of exogenous fibrinogen is usually necessary. Platelet aggregometers can also 
be used to measure shape change, in this case the platelets are treated in such a way that 
aggregation does not occur, e.g. by using EDTA to remove the extracellular calcium or, 
for washed platelets, by performing the assays in the presence of millimolar 
concentrations of calcium in the absence of added fibrinogen, although this second 
method is less commonly employed. Platelet responses may also be measured more 
directly by measuring either the inhibition of stimulated adenylate cyclase (in cases where 
the agonist does this) or by measuring the initial calcium transient induced by the agonist. 
Cyclase assays are performed by pre-labelling the platelets with radiolabelled adenine 
then extracting the labelled cAMP following stimulation (e.g. Haslam & Rosson, 1975). 
Relatively simple methods for the routine measurement of increases in platelet [Ca2+]; 
have only recently become available with the advent of cell permeant fluorescent 
indicators e.g. fura-2 (Giynkiewycz et al., 1985) or its predecessor quin-2 (Tsien, 1980).
1.6 Structure-Activity Relationships of the ADP Receptor
1.6.1 Agonists
Numerous analogues of ADP have been synthesized and tested for their activity as 
aggregating agents. A selection of the more interesting of these compounds is shown in 
figure 1.3. The receptor shows extreme sensitivity to modifications of the ADP molecule. 
Most modifications of the purine ring cause a decrease in agonist potency. Other naturally 
occurring nucleoside diphosphates (GDP, IDP, CDP and UDP) are effectively inactive as 
aggregating agents (Gaarder et a l , 1961). Modifications to the N1, C6, or C8 positions also 
result in loss of activity (Gaarder & Laland, 1964; Stone et a l , 1976), although 
8-bromo-ADP has recently been reported as an antagonist of ADP-induced aggregation 
(Jefferson et al., 1988). However, substitutions at the 2-position are tolerated and even 
some very large substituents such as spin labels can be added without apparent loss of 
potency (Robey et al., 1979). Indeed, some 2-substituted ADP analogues, notably
2-methylthio-, 2-chloro- and 2-azido-ADP are markedly more potent than the parent 
nucleotide (Cusack & Bom, 1977; Gough et a l, 1972; Maguire & Michal, 1968). 
Replacement of the D-ribose with its unnatural enantiomer L-ribose results in L-ADP 
which is devoid of agonist activity (Cusack et a l, 1979). Other modifications to the 
ribose moiety such as removal or inversion of the ring hydroxyls (as in 2-deoxy-ADP,
3-deoxy-ADP and adenine-9-p-D-arabinofuranoside 5f-diphosphate) or periodate 
cleavage of the ring to yield the corresponding linear dialdehyde results in analogues with 
markedly reduced, if any, aggregating activity (Gaarder et a l, 1961; Gaarder & Laland, 
1964; Pearce et al, 1978; Ragatz et a l, 1977).
Modifications of the 5-diphosphate chain also adversely effect agonist activity. Addition
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or removal of phosphate to make ATP or AMP result/ in competitive antagonists
L
(Macfarlane & Mills, 1975; Packham et al., 1972). However, AMP is a very weak 
competitive antagonist and its effects in vitro are thought primarily to be due to its 
degradation to adenosine (Packham et al., 1972) which will then inhibit platelet 
aggregation via its own receptor (see section 1.2). Replacement, of a bridging oxygen with 
methylene (to give adenosine 5?-(a,P-methylene)diphosphonate (AMPCP) and 
homo-ADP) results in analogues with only weak, if any, aggregating activity (Horak & 
Barton, 1974; Cusack et al., 1985) indeed AMPCP has been reported to be an apparently 
non-competitive antagonist of ADP-induced aggregation (Cusack & Pettey, 1988). This 
effect does not appear simply to be due to a reduction in polarity of these analogues 
relative to ADP, as suggested by Horak & Barton, as analogues of AMPCP which are 
isopolar with ADP also show reduced agonist activity. a,p-imido-ADP (AMPNP) is 
reported to be a partial agonist at the ADP receptor, whilst a,p-difluoromethylene-ADP 
and a,p-dichloromethylene-ADP were both reported to be inhibitors of ADP-induced 
aggregation (Cusack & Pettey, 1988), although the effect of the difluoro- analogue 
appeared to be non-competitive. This may imply an additional role of steric effects, as the 
geometry of the P-O-P bond in ADP will be somewhat different from that of the P-N-P or 
P-C-P bonds in these analogues, by analogy with similar ATP analogues (Yount et a l, 
1971). Replacement of ionized oxygen with ionized sulphur on either the inner or 
terminal phosphate groups, to give the analogues adenosine 5-0-(l-thiodiphosphate) 
(ADPaS) and adenosine 5'-0-(2-thiodiphosphate) (ADPpS), results in partial agonists of 
aggregation with intrinsic activities of about 0.75 (Cusack & Hourani, 1981a,b). ADPaS 
occurs as a pair of diastereoisomers, the receptor showing slight (~5 fold) selectivity for 
the Sp-isomer (Cusack & Hourani, 1981b). Replacement of a terminal hydroxyl with
fluorine results in an analogue with only weak aggregating activity (Cusack et al., 1985).
Far fewer analogues have been tested for their ability to inhibit stimulated adenylate 
cyclase activity. ADP and 2-chloro-ADP are approximately equipotent at inhibiting 
adenylate cyclase and inducing aggregation (Cusack & Hourani, 1982c). However, 
2-methylthio-ADP and 2-azido-ADP are far more potent as inhibitors of adenylate cyclase 
than they are as aggregating agents (Cusack & Hourani, 1982c; Macfarlane et a l , 1982; 
1983), whereas the phosphorothioate analogues of ADP show greater efficacy in inducing 
aggregation than they do in inhibiting adenylate cyclase. ADPPS is a partial agonist of the 
effect of ADP on adenylate cyclase with an intrinsic activity of 0.5 (Cusack & Hourani, 
1981a). However, although ADPaS is a partial agonist of aggregation, it acts as a pure 
competitive antagonist of the inhibition by ADP of stimulated adenylate cyclase. Again 
the ADP receptor showed ~5 fold stereoselectivity for the Sp-isomer (Cusack & Hourani, 
1981b). As with aggregation AMPCP has no agonist activity for the inhibition of 
adenylate cyclase (Cusack & Pettey, 1988). The dihalomethylenephosphonate analogues 
have effects on this response which are similar to their effects on aggregation (Cusack & 
Pettey, 1988).
1.6.2 Antagonists
A number of analogues of AMP and ATP have been tested as inhibitors of ADP-induced 
aggregation although in many cases competition has been assumed rather than being 
more rigorously established and the antagonist potency has not been fully evaluated 
(Gough et al., 1969; Gough et al., 1978; Kikugawa et al., 1973; Michal et al., 1969; 
Pearce et al., 1978). Several ADP analogues have now been reported as antagonists of
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aggregation as mentioned above, i.e. 8-bromo-ADP and AMPCP and its difluoro- and 
dichloro- analogues. A number of oc,o>diadenosine polyphosphates and more recently a 
number of methylenephosphonate and phosphorothioate analogues of P1,P4-diadenosine 
tetraphosphate (Ap4A) have also been reported to competitively inhibit ADP-induced 
aggregation (Harrison et al., 1975; Zamecnik et al., 1992). Of the antagonists whose 
competitive behaviour has been established, ATP has a reported Kj value of -20 juM 
against aggregation (Macfarlane & Mills, 1975). The most potent antagonist so far 
described is the SP-isomer of adenosine 5'-0-(l-thiotriphosphate) (ATPaS) which has a 
reported KB value of 4 pM against aggregation and 4.6 j l i M  against inhibition of adenylate 
cyclase (Cusack & Hourani, 1982b). Those compounds which have also been tested as 
antagonists of the cyclase effects of ADP have K; values which are similar to those 
obtained against aggregation (Cusack & Hourani, 1982b). Indeed, from this study, 
although only a limited number of ATP analogues was used, it would appear that the 
structural requirements of antagonists are largely the same as those of agonists, i.e. 
2-substituted analogues are more potent than the parent nucleotide whilst the methylene­
phosphonate analogues are less so. The phosphorothioate analogues form an exception to 
this as the ADP analogues are weaker aggregating agents than ADP whilst ATPaS is a 
rather more potent antagonist than ATP. Another group of antagonists which should be 
mentioned here are the 2-alkylthio- analogues of ATP and AMP. These molecules are 
selective but non-competitive inhibitors of ADP-induced aggregation (Cusack & Hourani, 
1982a). Furthermore, these analogues could not completely abolish the effect of a 
maximally effective concentration of ADP (for aggregation) causing a maximum of only 
-50% inhibition (Cusack & Hourani, 1982a). Interestingly, 2-methylthio-adenylyl 
5'-(p,y-methylene)diphosphonate (MeSAMPPCP) whilst only inhibiting maximal
aggregation by -50% was able to completely inhibit the effect of ADP on adenylate 
cyclase (Cusack et al., 1985; Hourani et al., 1986). Schild analysis of this effect of 
MeSAMPPCP gave a slope of 1.12 which suggests that this effect was competitive. This 
suggests that the inhibition of adenylate cyclase by ADP, or perhaps an effect associated 
with activation of the same G-protein (e.g. production of a calcium mobilising second 
messenger) may be important for the full effect of ADP on aggregation. In support of this 
is the observation that whilst MeSAMPPCP inhibited aggregation induced by ADPpS, a 
partial agonist of adenylate cyclase inhibition, in a manner similar to its inhibition of 
ADP-induced aggregation, it was not able to inhibit aggregation induced by ADPaS, an 
analogue which does not inhibit adenylate cyclase but which antagonizes this effect 
(Cusack et al., 1985; Hourani et al., 1986). The structures of a selection of ATP 
analogues is shown in figure 1.4.
1.6.3 Multiple ADP Receptors?
The lack of correlation between the abilities of the 2-substituted and phosphorothioate 
analogues of ADP to inhibit adenylate cyclase and to induce aggregation has led to the 
suggestion that these effects are mediated by two different receptors (Colman et a l, 
1980; Macfarlane et al., 1982; 1983). Support for this suggestion has been claimed from 
observations with the affinity reagent 5'-p-fluorosulphonylbenzoyladenosine (FSBA) (the 
structure of which is shown in figure 1.3) which inhibits ADP-induced shape change and 
aggregation but does not affect the inhibition by ADP of adenylate cyclase. [3H]-FSBA 
labels a 100 kDa protein in the platelet plasma membrane which has been called 
’aggregin’ and proposed to be the ADP receptor which mediates aggregation (Colman, 
1992). However, the incorporation of 3H from labelled FSBA into platelet membranes
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is only inhibited at very high concentrations of ADP and ATP (10 mM) and is also 
blocked by similar concentrations of adenosine, 2-chloroadenosine, GDP and UDP 
(Bennett et al., 1978) none of which are ADP receptor ligands. The incorporation of 
FSBA into platelet membrane proteins is not therefore consistent with the known 
pharmacology of the ADP receptor. Also a high concentration (10 mM) of FSBA does not 
inhibit the binding of [32P]-MeSADP, a potent ADP agonist, to platelets (Mills et al., 
1985). Due to its relatively high potency as an inhibitor of adenylate cyclase compared to 
its ability to induce aggregation P2P]-MeSADP has been claimed to be a selective ligand 
for the ADP receptor which mediates inhibition of adenylate cyclase (Macfarlane et al., 
1983). However, since MeSADP is also a potent aggregating agent and binding studies 
using this ligand showed no evidence for two binding sites (Scatchard plots being linear) 
(Macfarlane et al., 1983) it must be assumed that MeSADP induces both of its effects via 
a single class of receptor, which is not blocked by FSBA. It has also been shown that 
FSBA does not inhibit the mobilization of calcium induced by ADP (Rao & Kowalski, 
1987), a response which is thought to be the direct trigger of aggregation. The 
observations that FSBA cannot inhibit either of the second messenger effects induced by 
ADP, that it does not inhibit the binding to platelets of a potent aggregating agent and that 
the incorporation of FSBA can be blocked by compounds which do not interact with the 
ADP receptor (e.g. adenosine) would suggest that FSBA does not, in fact, interact with 
the ADP receptor and that it may exert its inhibitory effects by interacting with a site 
further along the pathway which leads to aggregation. Interesting, in the light of the above 
suggestion, is the observation that FSBA can also inhibit shape change and aggregation 
induced by a number of other aggregating agents, e.g. TXA^ collagen, thrombin and 
adrenaline (for a review see Colman, 1990). This was taken by these authors to imply a
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central role for ADP in the effects of other aggregating agents. However, primary 
aggregation induced by adrenaline, for example, occurs prior to the release of ADP 
(Charo et al., 1977) and is not blocked by ATP (a selective ADP receptor antagonist) 
(Macfarlane & Mills, 1975), strongly suggesting that this response is independent of 
ADP. Thus the ability of FSBA to inhibit responses to these agents can equally well be 
explained by a non-selective inhibition by FSBA of a common event which occurs in 
response to all of these agonists. Interestingly, the molecular weight of aggregin (the 
protein labelled by [3H]-FSBA), 100 kDa, is the same as that of glycoprotein Hla which 
forms part of the agonist-inducible fibrinogen receptor which is essential for aggregation 
in response to most aggregating agents. The ability of FSBA to modify glycoprotein Ilia 
would, therefore, explain quite well its non-specific ability to inhibit platelet aggregation. 
However, Colman et al (1988) have shown quite convincingly that aggregin is a distinct 
polypeptide from Gp Ilia making this suggestion untenable but still not confirming 
aggregin as an ADP receptor.
Another possible explanation for these differences in potency is that ADP acts at a single 
class of receptor which is coupled via two different effector mechanims (Cusack & 
Hourani, 1982b). Different regions of the ADP molecule may be involved in activating 
these different effector mechanisms and structural analogues of ADP would not, then, 
necessarily be expected to exhibit the same potency in inducing these effects. Support for 
this second hypothesis comes from a detailed study of the effects of a number of ADP 
receptor antagonists (Cusack & Hourani, 1982b). All of these antagonists were shown to 
be competitive by Schild analysis and there was a good correlation between the pAs 
values obtained for these antagonists as inhibitors of aggregation and as inhibitors of the 
effects of ADP on adenylate cyclase. Also binding studies using the agonists 2-azido-ADP
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and MeSADP revealed only a single class of binding site (Macfarlane et al., 1982; 1983). 
As both of these compounds are potent aggregating agents as well as inhibitors of 
adenylate cyclase this must suggest that the effects of ADP are mediated by only a single 
class of receptor. In a recent study using a novel photoaffinity reagent 
2-azidophenylethylthio-ADP, which was shown to be both an aggregating agent and an 
inhibitor of stimulated adenylate cyclase activity, only a single 43 kDa protein was 
labelled (Cristalli & Mills, 1993). In contrast, Jefferson et al. (1988) have shown two 
binding sites for [3H]-ADP on formaldehyde fixed platelets. However, the process of 
formaldehyde fixation causes extensive cross linking of proteins throughout the cell, 
including cell membrane proteins such as receptors. Indeed, these authors state that the 
fixation was performed in order to inactivate ADP metabolising enzymes which are a 
complicating factor in binding studies with adenine nucleotides and their analogues in 
unfixed platelets. If fixation is able to denature the ADP binding sites of enzymes such 
that they no longer possess catalytic activity, it is not unreasonable to assume that the 
ADP receptor binding site may be similarly denatured. This, therefore, casts doubt as to 
whether either of the binding sites detected in this study would represent a functional 
ADP receptor in native platelets. Also, the structure-activity relationships of these two 
binding sites were not consistent with those obtained in functional studies further 
complicating the acceptance of either of these sites as an ADP receptor. Two recent 
reports suggest the presence of an adenine nucleotide binding site on the Gp Ilb-IIIa 
complex. Greco et al. (1991) used [35S]-ATPaS as a photoaffinity reagent (activating the 
purine ring by exciting it with light at 254 nm) and labelled a single 120 kDa protein 
which they showed to be identical to the a-chain of Gp lib using several techniques. 
Mayinger & Gawaz (1992) used the photoaffinity analogue 8-azido-ATP labelled with 32P
45
on the y-phosphate and labelled two membrane glycoproteins which they showed to be 
glycoproteins lib and Ilia by Western blotting with specific monoclonal antibodies. This 
labelling was blocked in the presence of 1 mM ATP. However, this binding site is 
unlikely to represent an ADP receptor as Greco et al. (1992) subsequently showed that 
this binding site could also be photo-labelled by 35S labelled guanosine 
5'-0-(l-thiotriphosphate) (GTPaS) and uridine 5-0-(l-thiotriphosphate) (UTPaS) which 
were both shown in this study to be only very weak inhibitors of responses to ADP. Also, 
platelets from thrombasthenic patients are still able to respond to ADP but lack these two 
glycoproteins.
Thus, the weight of current evidence would seem to support the hypothesis that only a 
single class of ADP receptor is responsible for the various responses of platelets to ADP, 
the observed lack of correlation between the potencies of some compounds as agonists of 
these responses simply being a reflection of differing efficacy of these compounds in 
activating the signal transducing mechanisms associated with this ADP receptor. This 
ADP receptor would appear to be distinct from the Gp Ilb-IIIa complex and from 
aggregin the 100 kDa protein labelled by FSBA but may be identical with the 43 kDa 
protein which is photoaffinity labelled by 2-azidophenylethylthio-ADP.
1.7 Aim of this Thesis
The aim of this thesis was to further characterize the pharmacology of the human platelet 
ADP receptor, both to address the question of whether there are one or two receptors on 
human platelets mediating the response to ADP and to compare the ADP receptor with 
other P2-purinoceptors subtypes.
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CHAPTER 2 
STUDIES ON INCREASES IN 
CYTOSOLIC CALCIUM 
CONCENTRATION
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2.1 Introduction
The second messenger response of platelets which is thought to be most important in the 
induction of shape change and aggregation by ADP is an increase in cytosolic calcium 
concentration (see section 1.4 of the General Introduction). The kinetics of this increase 
have been extensively studied, and there is good evidence that the increase in intracellular 
calcium concentration induced by ADP involves both the influx of extracellular calcium 
via an ADP-gated cation-channel and the release of calcium from intracellular stores 
(Hallam & Rink, 1985a, b; Mahaut-Smith et a l, 1990; 1992; Sage & Rink, 1986; 1987; 
Sage et a l, 1989; 1990). The kinetics of mobilization of calcium from intracellular stores 
are consistent with the production of a second messenger, however the identity of this 
messenger has yet to be unequivocally determined (see section 1.4.2). Influx of 
extracellular calcium is sensitive to inhibition by tyrosine kinase inhibitors suggesting 
that the ADP-gated ion-channel or store regulated influx may be activated by tyrosine 
phosphorylation (Sargeant et a l , 1993b). The phosphorylation of a 130 kDa protein was 
consistently inhibited by the tyrosine kinase inhibitors used in this study and may 
therefore represent this channel or a subunit thereof. However, apart from a brief 
statement by Drummond and MacIntyre (1987) that ATP inhibits ADP-induced increases 
in [Ca2+]j (which is consistent with the known pharmacology of the ADP receptor), very 
little is known about the structure-activity relationship of the ADP receptor which 
induces this response. Thus the effects of ADP, ATP and a number of adenine nucleotide 
analogues whose effects on ADP-induced aggregation and inhibition adenylate cyclase 
have previously been characterised were determined. A brief summary of the known 
effects of the compounds used in the present study is given below (for further details see 
section 1.6 of the General Introduction).
MeSADP is a potent aggregating agent and inhibitor of adenylate cyclase being about 5 
fold more potent than ADP as an aggregating agent (Macfarlane et al., 1983) and about 
200 fold more potent than ADP as an inhibitor of adenylate cyclase (Macfarlane et al, 
1983). Sp-ADPocS and ADPpS are both partial agonists of aggregation having intrinsic 
activities of 0.75 (Cusack & Hourani, 1981a, b). ADPpS is also a partial agonist of 
adenylate cyclase inhibition, although in this case its intrinsic activity is only 0.5, whilst 
ADPaS acts as a pure antagonist of this response. Of the known competitive antagonists 
of ADP-induced aggregation and inhibition of adenylate cyclase (Cusack & Hourani, 
1982b) Sp-ATPaS, Cl-ATP, AMPPCP and Ap5A were tested for their ability to inhibit 
ADP-induced increases in [Ca2+]j. The effects of the compounds MeSATP, AMPCPP and 
UTP were also determined. MeSATP has been shown to be a selective but 
non-competitive inhibitor of ADP-induced aggregation (Cusack & Hourani, 1982a), 
however a close structural analogue, MeSAMPPCP, appeared to be a competitive 
inhibitor of the effects of ADP on adenylate cyclase (Hourani et al., 1986; see section
1.5.2 of the General Introduction for further discussion). AMPCPP has been reported to 
have no effect on ADP-induced aggregation (Lips et al., 1980), its effects on inhibition by 
ADP of adenylate cyclase have not been reported. There has been increasing interest 
recently in the effect of UTP in some tissues which appear to possess atypical P2Y 
receptors (O'Connor et al., 1991) and it was, therefore, of interest to determine the effect 
of this compound at the ADP receptor. The effects of SP-ATPpS were determined both on 
calcium mobilization and ADP-induced aggregation. The effects of ATPpS on 
aggregation have not previously been studied and were, therefore, of interest in further 
characterising the pharmacology of this response as well as for comparing it with calcium 
mobilization.
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Some of the results presented here have been published (Hall & Hourani, 1993), and a 
copy of this paper is included at the back of this thesis.
2.2 Materials and Methods
2.2.1 Materials
ADP, ATP, AMPCPP, AMPPCP, adenosine 5-phosphorothioate (AMPS), bovine serum 
albumin (BSA), creatine kinase (type 1 from rabbit muscle), creatine phosphate, 
diethylaminoethyl (DEAE)-sephadex A25, Pl,P5-diadenosine pentaphosphate (Ap5A), 
[ethylene-bis(oxyethylenenitrilo)] tetraacetic acid (EGTA), fura-2-AM, myokinase 
(chicken muscle), myosin (rabbit muscle), phosphoenolpyruvate, prostacyclin, pyruvate 
kinase (type HI from rabbit muscle), tetrabutylammonium hydrogen sulphate, 
tris(hydroxymethyl)aminomethane (tris), triton X-100 and UTP were obtained from 
Sigma Chemicals Company. ADPPS was obtained from Boehringer Mannheim. ATPaS 
was obtained from Boehringer Mannheim and purified as described in section 2.2.6 or 
synthesised enzymatically as described in section 22.12. MeSATP, MeSADP and 
2-chloro-ATP (Cl-ATP) were obtained from Research Biochemicals Incorporated and 
purified as described in section 2.2.6. ADPaS and ATPpS were synthesised 
enzymatically as described in sections 2.2.7.1 and 22 .13 , respectively. ADP, ATP, 
AMPPCP, Ap5A and UTP were obtained as the sodium salt, other nucleotides were 
obtained as the lithium salt. HPLC solvents were obtained from Fisons Scientific 
Apparatus. Prostacyclin was dissolved at 100 pg/ml in 10 mM NaOH. Fura-2-AM was 
dissolved at 5 mM in dimethylsulphoxide. Both were stored frozen at -20°C. All other 
drugs were dissolved in water. Nucleotides were stored frozen in solution.
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2.2.2 Platelet Aggregation Studies
Blood (9 volumes) from healthy human volunteers, who said they had not taken any drugs 
for the previous 10 days, was drawn into 1 volume of 3.8 % tri-sodium citrate, 
centrifuged at 260 g for 20 min and the supernatant platelet-rich plasma (PRP) was 
removed. Platelet-poor plasma was obtained by centrifuging PRP in a microfuge for 1 
min. Aliquots (300 jul) of PRP were taken and incubated at 37°C for 3 min prior to 
transfer to a Chrono-Log Lumi-Aggrometer. Aggregation was quantified as the maximal 
rate of increase in light transmission (in arbitraiy units per min) through the stirred 
sample, relative to platelet-poor plasma, on addition of agonist. The PRP was maintained 
at 37°C within the aggregometer and was stirred at 1000 rpm. Agonists were added in 10 
pi of water. As adenine nucleotides are known to be rapidly degraded in plasma (Maguire 
& Satchell, 1981) antagonists, where used, were added simultaneously with the agonist to 
avoid possible complicating effects of pharmacologically active degradation products.
2.2.3 Loading of Platelets with Fura-2
Platelets were loaded with fura-2 by a modification of the method of Rink & Sage (1987). 
Blood (6 volumes) was drawn into 1 volume of acid-citrate-dextrose anticoagulant (25 g/1 
tri-sodium citrate dihydrate, 15 g/1 citric acid monohydrate, 20 g/1 glucose) and 
centrifuged for 20 min at 260 g. The supernatant PRP was removed and incubated at 
37°C for 45 min in the presence of 4 pM fura-2-AM. The fura-2-loaded platelets were 
then collected by centrifugation at 680 g for 20 min, in the presence of 1 pM prostacyclin 
(to prevent aggregation), and resuspended at 1 x 108/ml in HEPES-saline (145 mM NaCl, 
5 mM KC1,1 mM MgC^, 10 mM N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid
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(HEPES), 10 mM glucose and 2 mg/ml BSA, adjusted to pH 7.4 with 1 M NaOH). 
Aliquots of platelet suspension (0.7 ml) were incubated at 37°C in siliconised glass 
aggregometer tubes for 3 min in the presence of 1 mM CaCl2 and transferred to a 
Perkin-Elmer LS50 luminescence spectrometer for estimation of cytosolic calcium 
concentration.
2.2.4 Calcium Measurement
The fura-2-loaded platelet suspension was maintained at 37°C and stirred whilst it was 
excited alternately with light at 340 ran and 380 nm. The emitted light intensity was 
measured at 510 nm. The ratio, R, of the emitted light intensity upon excitation at these 
two wavelengths was determined and used to calculate the cytosolic calcium 
concentration. The maximal intensity ratio (Rmax) was determined following lysis of the 
platelets with 0.1 % Triton X-100 and the minimum intensity ratio (R ^) was determined 
by subsequent addition of 20 mM tris followed by 10 mM EGTA. These measurements 
were used to calibrate the fluorescence signal by the Perkin-Elmer Intracellular 
Biochemistry programme which calculates cytosolic calcium concentrations from the 
sample fluorescence intensity ratios using the following formula (taken from 
Grynkiewicz et a l, 1985):
[Ca2+]i = Kd ((R - Rmin) / ( R ^  - R)) SFB
where, KD is the apparent dissociation constant of the fura-2.calcium complex (= 225 
nM) and SFB is the ratio of the fluorescence intensities of free fura-2 and its calcium 
complex when excited at 380 nm.
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Agonists were added in 14 pi of water and antagonists, where used, were added 
simultaneously with the agonist. Responses were quantified as the maximal change in 
cytosolic calcium concentration following addition of the agonist. Log 
concentration-response curves were obtained at least three times with blood from 
different donors and the results pooled. EC50 values were obtained by regression of the 
linear parts of the pooled log concentration-response curves and dose ratios for 
antagonists were calculated from the EC50 values in the presence and absence of 
antagonist. Where Schild analysis was not performed the apparent KD values for 
antagonists were obtained from the dose ratios using the formula KD = concentration of 
antagonist / (dose ratio - 1) and pA2 values were calculated as -log10KD. Statistical 
significance was determined by Student’s t-test.
2.2.5 HPLC Separation of Nucleotides
To determine the purity of the adenine nucleotides used in this study nucleotides were
d
separated by ion-paired reverse-phase HPLC on a Techsphere 50DS column (15 cm x 3.9 
mm id). The injection volume was 50 pi. For 2-substituted nucleotides the mobile phase 
consisted of two buffers: 100 mM KHjPO^ 8 mM tetrabutylammonium hydrogen 
sulphate, pH 6.0 (buffer A) and a mixture of buffer A and acetonitrile (60:40, v/v) (buffer 
B). The column was eluted at a flow rate of 1.3 ml/min with the following gradient: 2.5 
min at 100 % A, 2.5 min up to 20 % B, 5 min up to 40 % B, 3 min up to 100 % B. The 
column was held at 100 % B for a further 7 min and then returned to 100 % A over 5 min. 
The column was maintained in 100 % buffer A for a further 15 min prior to injection of 
the next sample. Nucleotides were detected photometrically at the appropriate 
wavelength (see section 2.2.6, Nucleotide Separation).
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For the phosphorothioate analogues buffer A was 100 mM KEyPC ,^ pH 7.0 containing 8 
mM tetrabutylammonium hydrogen sulphate and buffer B was a mixture of buffer A and 
methanol (70:30, v/v). The column was eluted at a flow rate of 1.3 ml/min with the 
following gradient: 2.5 min at 100 % A, 7.5 min up to 100 % B, hold at 100 % B for 10 
min. The column was returned to 100 % A over 5 min and maintained at 100 % A for a 
further 10 min prior to injection of the next sample.
Unsubstituted nucleotides could be resolved using either of these HPLC systems, 
although the system which used acetonitrile in buffer B was routinely used. Retention 
times for the nucleotides used in this study and some of their degradation products in 
these HPLC systems are shown in table 2.1.
2.2.6 Nucleotide Purification
Where necessary nucleotides were purified by ion-exchange chromatography on a 30 x 
1.5 cm DEAE-sephadex column, eluting with a 2 1 linear gradient of 1 - 800 mM 
triethylammonium bicarbonate, collecting 12-13 ml samples. The fractions containing the 
nucleotides were identified spectrophotometrically at the maximally absorbing 
wavelength. This corresponds to 273 nm for 2-methylthio-substituted adenine 
nucleotides, 266 nm for 2-chloro-substituted adenine nucleotides and 259 nm for 
nucleotides with unmodified adenine moieties. Fractions containing the required 
nucleotides were pooled and concentrated with removal of the buffer salt as follows. The 
pooled aqueous fractions were rotaiy evaporated to diyness in a 1 1 vessel at a 
temperature not greater than 30°C. Under these conditions the triethylammonium 
bicarbonate dissociates into its molecular components, triethylamine, carbon dioxide and 
water, all of which are evaporated from the sample. Residual triethylammonium
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Nucleotide
Retention time / min
Buffer B 
40% Acetonitrile
Buffer B 
30% Methanol
Adenosine 8.9 8.7
AMP 9.3 6.7
ADP 11.5 11.2
ATP 13.6 12.3
AMPS 10.9 10.5
ADPccS 13.6 12.9
ATPaS 15.8 13.6
ADPPS 13.2 12.1
ATPpS 13.5 13.0
MeSADP 15.8 n.d.
MeSATP 16.4 n.d.
Cl-ATP 15.5 n.d.
Ap5A n.d. 14.4
AMPCPP 12.6 n.d.
AMPPCP 12.6 n.d.
Table 2.1 A comparison of the retention times of various adenine nucleotide analogues 
in the two HPLC systems used in this study (n.d. = not determined).
bicarbonate and water were removed from the sample by twice dissolving the residue in 
methanol (50 ml) and rotary evaporating. The residue was then transferred to a 25 ml 
vessel in 5 ml of methanol and evaporated to dryness along with a second 5 ml methanol 
wash of the original vessel. Residual methanol was removed by dissolving the sample in 
water (5 ml) and evaporating to dryness. Finally the nucleotide was dissolved to a known 
concentration (determined photometrically using published extinction coefficients) in 
water. This method of purification yields the nucleotide as the triethylammonium salt.
2.2.7 Nucleotide Synthesis
2.2.7.1 Synthesis ofSp-ADPaS
Initially attempts were made to synthesize SP-ADPaS from AMPS using myokinase (MK) 
and ATP. MK has been reported to stereospecifically phosphorylate AMPS to Sp-ADPaS 
(Eckstein & Goody, 1976; Sheu & Frey, 1977). Creatine kinase (CPK) and creatine 
phosphate (CrP) were included in the reaction mixture to regenerate ATP. CPK 
specifically phosphorylates the Rp-isomer of ADPaS (Eckstein & Goody, 1976) and 
should not, therefore, phosphorylate the desired product of the reaction, SP-ADPaS. The 
reactions which it was assumed would occur were:
myokinase
AMPS + ATP-----------------» Sp-ADPaS + ADP
creatine
ADP + CrP-----------------> ATP + creatine
kinase
However, when the reaction was carried out the final product was not Sp-ADPaS but 
SP-ATPaS. Presumably the MK was able to further phosphorylate any ADPaS which was
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formed, i.e. Sp-ADPaS + ADP > Sp-ATPaS + AMP. Thus, this system could not be
used to synthesize SP-ADPaS, however, it was used in initial syntheses of SP-ATPaS (see 
section 2.2.7.2).
Sp-ADPaS was subsequently synthesised by the enzymatic dephosphorylation of 
Sp-ATPaS with myosin (Jaffe & Cohn, 1978). The reaction mixture contained: 100 mM 
HEPES, pH 7.4, 30 mM KC1, 3 mM CaCl2, 3.2 mM ATPaS, 0.5 mg/ml myosin, 5 % 
glycerol. The reaction was carried out at 37°C in a total volume of 10 ml and was 
followed by HPLC (see section 2.2.5) taking 10 pi samples every 35-40 min. The reaction 
was complete within 35 min and was terminated by addition of 1 ml of 50 % 
trichloroacetic acid (TCA). The precipitated protein was removed by filtration and the 
filtrate was neutralised with NaOH and applied to an ion-exchange column (see section 
2.2.6). The resulting ADPaS was at least 95 % pure by HPLC.
22.12  Synthesis of SP-ATPaS
The Sp-isomer of ATPaS was initially synthesised using the coupled reactions myokinase 
and CPK using ATP and CrP as the phosphoryl group donors (see section 2.2.7.1). In 
subsequent syntheses pyruvate kinase (PK), which is specific for the phosphorylation of 
Sp-ADPaS, and phosphoenolpyravate (PEP) were used instead of CPK and CrP. The 
overall reaction in this case being:
MK/PK/ATP
AMPS + 2 PEP--------------------> Sp-ATPaS + 2 pyruvate
For the synthesis of SP-ATPaS using creatine kinase the reaction mixture contained: 50 
mM tris.HCl, pH 8.0, 3 mM MgCl2, 6.7 mM AMPS, 7 mM ATP, 10 mM creatine
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phosphate, 50 units/ml myokinase and 20 units/ml creatine kinase. The reaction was 
carried out at 37 °C in a total volume of 10 ml and was followed by HPLC (see section 
2.2.5) taking 10 pi samples every 35-40 min. After 4 hours the reaction reached 
equilibrium and was applied to an ion-exchange column to separate the nucleotides (see 
section 2.2.6). The resulting ATPaS was at least 95 % pure by HPLC and was a substrate 
for myokinase confirming it as the Sp-isomer (Eckstein & Goody, 1976).
For the synthesis of Sp-ATPaS using pyruvate kinase the reaction mixture contained: 50 
mM tris.HCl, pH 8.0, 3 mM MgCl2, 100 mM KC1, 6.7 mM AMPS, 0.2 mM ATP, 15 mM 
phosphoenolpyruvate, 50 units/ml myokinase and 20 units/ml pyruvate kinase. The 
reaction was carried out at 37°C in a total volume of 10 ml and was followed by HPLC 
(see section 2.2.5) taking 10 pi samples every 35-40 min. After 5 hours approximately 50 
% of the AMPS had been converted to ATPaS and the reaction was terminated by the 
addition of 1 ml of 50 % TCA. The precipitated protein was removed by filtration and the 
filtrate neutralised with NaOH. The ATPaS was separated by ion-exchange 
chromatography (see section 2.2.6). The Sp-ATPaS produced was at least 97 % pure by 
HPLC.
2.2.7.3 Synthesis of Sp-ATPpS
ATPpS was synthesised by the phosphorylation of ADPpS with pyruvate kinase. This 
reaction is specific for the formation of the SP-isomer (Eckstein & Goody, 1976; Jaffe & 
Cohn, 1978). The reaction mixture was of the following composition: 50 mM tris.HCl, 
pH 8.0, 100 mM KC1, 3 mM MgC^, 3.5 mM ADPpS, 4 mM phosphoenolpyruvate, 15 
units/ml pyruvate kinase. The reaction was carried out at 37 °C in a total volume of 10 ml
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and was followed by HPLC. After 3 hours 20 min the reaction was terminated by 
applying the reaction mixture to an ion-exchange column. The resulting ATPpS was 95 
% pure by HPLC. This ATPpS was heated at 60°C to inactivate contaminating enzyme 
(subsequent nucleotide syntheses were terminated by addition of TCA to remove the 
enzymes before they were applied to the ion-exchange columns). The precipitate was 
removed by filtration. This heat treatment left the ATPpS contaminated by approximately 
15 % AMP. This quantity of contaminating AMP was not sufficient at the concentrations 
of ATPpS used in this study to have any significant antagonistic effect (Packham et a l, 
1972). For ATPpS the concentrations given in the text refer to the concentration of 
ATPpS present not the total nucleotide concentration, due to this relatively large impurity 
content.
2.3 Results
A typical trace of the changes in fluorescence intensity ratio of a sample of fura-2-loaded 
platelet suspension on addition of ADP is shown in figure 2.1a along with a trace 
showing the determination of Rmin and R ^ . Figure 2.1b shows the corresponding graph of 
the changes in cytosolic calcium concentration calculated from the fluorescence intensity 
ratios.
ADP induced concentration-dependent increases in platelet cytosolic calcium 
concentration, with an EC50 value of 0.8 juM. This effect was inhibited by ATP which 
caused parallel rightward shifts in the ADP log concentration-response curve (figure 
2.2a). Schild analysis of this inhibition by ATP resulted in a slope of 0.95 ± 0.07 (not 
significantly different from unity, p>0.5) and a pA2  value of 5.01 (corresponding to a KD
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Figure 2.1 A typical fluorimeter trace from dual wavelength calcium measurement, 
(a) A fluorimeter trace showing the change in fluorescence intensity ratio of a sample of 
fura-2-loaded platelets on addition of ADP (100 pM) (solid line) and a calibration trace 
(dashed line), (b) The data shown in (a) converted to calcium concentrations.
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Figure 2.2 The effect of ATP on increases in cytosolic calcium concentration ([Ca2+]j) in 
human platelets induced by ADP. (a) Effect of ADP alone (•) or in the presence of ATP 
at 100 pM (■), 200 pM (A), 400 pM or 800 pM (▼). Each point is the mean of at least 
3 determinations, and the vertical bars show the s.e. mean, (b) The Schild plot of the data 
presented in (a). For abbreviations, see text.
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value of 9.8 pM) (figure 2.2b). Although only one concentration was tested, the 
analogues Cl-ATP (30 pM), ATPaS (10 pM), ATPPS (8.5 pM), Ap5A (200 pM) and 
AMPPCP (100 pM) (figure 2.3a-d and figure 2.4a) also inhibited ADP-induced increases 
in [Ca2+],. in an apparently competitive manner, i.e. they caused parallel, rightward shifts 
of the log concentration-response curve with no significant depression of the maximal 
response. However, little inhibition was observed in the presence of AMPCPP (100 pM) 
or UTP (100 pM) (figure 2.4b and c). The pA  ^values for these antagonists, derived from 
the dose-ratios, were 5.60 for Cl-ATP, 5.92 for ATPaS, 5.96 for ATPpS, 5.10 for Ap5A 
and 4.27 for AMPPCP, whilst those for AMPCPP and UTP were both less than 3.82. 
ATPpS also appeared to act as a competitive antagonist of ADP-induced aggregation 
with an apparent affinity similar to that of ATPaS, giving a against ADP-induced 
aggregation of 5.46 (figure 2.5). MeSATP (50 pM) also inhibited ADP-induced calcium 
mobilization, but this inhibition was not competitive and could not be overcome by a high 
concentration of ADP (300 pM) (figure 2.4d).
MeSADP also induced increases in cytosolic calcium concentrations and was about 20 
times more potent than ADP, with an EC50 value of 41 nM. This effect of MeSADP was 
inhibited by ATP (100 pM) in an apparently competitive manner (ATP causing parallel, 
rightward shifts in the log concentration-response curve with no apparent decrease in the 
maximal response), giving a pA  ^for ATP of 4.66 (figure 2.6). ADPaS and ADPpS each 
caused increases in cytosolic calcium concentration, but in each case achieved only about 
60 % of the maximum effect of ADP even at high concentration (100 or 300 pM) (figure 
2.7a and b). ADPaS was approximately 8 fold more potent than ADPpS at causing these 
increases having an EC50 value of -0.5 pM compared to ~4 pM for ADPpS. The effects
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Figure 2.3 Increases in platelet cytosolic calcium concentration ([Ca2+];) induced by 
ADP alone (•) or in the presence (■) of (a) Cl-ATP (30 pM), (b) ATPaS (10 pM), (c) 
ATPpS (8.5 pM) or (d) Ap5A (200 pM). Each point is the mean of at least 3 
determinations, and the vertical bars show the s.e. mean. For abbreviations, see text.
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Figure 2.4 Increases in platelet cytosolic calcium concentration ([Ca2+]j) induced by 
ADP alone (•) or in the presence (■) of (a) AMPPCP (100 pM), (b) AMPCPP (100 pM), 
(c) UTP (100 pM) or (d) MeSATP (50 pM). Each point is the mean of at least three 
determinations, and the vertical bars show the s.e. mean. For abbreviations, see text.
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Figure 2.5 Platelet aggregation induced by ADP alone (•) or in the presence of ATPpS 
(17 pM) (■) or ATPaS (20 pM) (▲). Each point is the mean of three determinations and 
the vertical bars show the s.e. mean. For abbreviations, see text.
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Figure 2.6 Increases in platelet cytosolic calcium concentration ([Ca2+]s) induced by 
ADP (□), MeSADP (O) or MeSADP in the presence of ATP (100 pM) (•). Each point is 
the mean of at least three determinations, and vertical bars show the s.e. mean. For 
abbreviations, see text.
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Figure 2.7 Increases in platelet [Ca2+]j induced by ADP (•) or by (a) ADPaS (■) or (b) 
ADPpS (A). Effect of (c) ADPaS (■,□) or (d) ADPpS (A ,A) on platelet [Ca2^  in the 
absence (closed symbols) or presence (open symbols) of ATP (100 juM). Each point is the 
mean of at least three determinations, and vertical bars show the s.e. mean. For 
abbreviations, see text.
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of ADPaS and ADPpS were inhibited by ATP (100 juM), giving apparent pA  ^values for 
ATP of 5.55 and 5.32 respectively (figure 2.7c and d).
2.4 Discussion
These results represent the first detailed investigation into the structure-activity 
relationships of the ADP receptor which mediates increases in cytosolic calcium 
concentration in human platelets. As expected the log concentration-response curve to 
ADP itself, giving an EC50 value of 0.8 pM, is similar to that usually found in for the 
induction of aggregation, in washed platelets or in PRP, and it is also similar to that found 
in previous studies on the concentration-dependence of the effect of ADP on platelet 
cytosolic calcium concentration (Drummond & MacIntyre, 1987; Sage & Rink, 1987). 
MeSADP was -20 fold more potent than ADP at inducing increases in platelet cytosolic 
calcium concentration. This values lies between its reported potency ratios for the 
induction of aggregation or the inhibition of adenylate cyclase of -5 and -200, 
respectively (Macfarlane et a l , 1983) but is somewhat closer to that reported for 
aggregation. The effect of MeSADP on cytosolic calcium concentration, like that on 
aggregation and stimulated adenylate cyclase activity (Cusack & Hourani, 1982c), was 
competitively inhibited by ATP with a pA  ^ value similar to that shown by ATP at 
inhibiting the effects of ADP, indicating that MeSADP is acting via the ADP receptor. 
The phosphorothioate analogues of ADP, ADPaS and ADPpS, each achieved lower 
maximal increases in cytosolic calcium concentration than did ADP, with ADPaS being 
more potent than ADPpS. The effects of these two analogues were also inhibited by ATP 
with an appropriate pAs value, indicating that these compounds are also acting via the 
ADP receptor, presumably as partial agonists. Their effects on platelet cytosolic calcium
concentration, therefore, exactly mimic their effects on platelet aggregation, where they 
act as partial agonists, with ADPaS being more potent than ADPpS. However, at least in 
the case of ADPaS, the effect differs from that on stimulated adenylate cyclase activity 
where ADPaS acts as an antagonist (Cusack & Hourani, 1981a,b). Overall, therefore, the 
ability of agonists to cause increases in platelet cytosolic calcium concentration seems to 
agree more closely with their ability to induce aggregation than their ability to inhibit 
stimulated adenylate cyclase activity supporting the idea that calcium mobilization is the 
most important signal for ADP-induced aggregation. The lack of correlation between the 
ability of these agonists to induce increases in cytosolic calcium concentration and to 
inhibit adenylate cyclase also suggests that the inhibition of adenylate cyclase is not 
simply a consequence of this increase in calcium concentration but is a separately 
mediated event.
Of the analogues tested as antagonists ATP, Cl-ATP, ATPaS, ATPpS, Ap5A and 
AMPPCP caused apparently competitive inhibition of the effect of ADP-induced calcium 
mobilization, although apart from ATP only one concentration of each antagonist was 
tested. AMPCPP and UTP were essentially inactive as inhibitors. The weak action of 
AMPCPP is in agreement with its reported lack of inhibitory activity on ADP-induced 
aggregation (Lips et al., 1980), and confirms the sensitivity of the ADP receptor to 
modifications of the phosphate chain. The lack of inhibitory effect of UTP is also not 
unexpected as, although UTP itself has not been tested as an inhibitor of ADP-induced 
aggregation, the corresponding diphosphate, UDP, is 500 - 1000 fold less potent as an 
aggregating agent than ADP (Chambers et al., 1968), and the phosphorothioate analogue 
of UTP, UTPaS, is much less potent than ATPaS as an inhibitor of ADP-induced shape
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change and aggregation, with 700 - 800 joM being required to fully inhibit aggregation 
induced by 5 juM ADP (Greco et al., 1992). In this study [3H]-ADP binding was displaced 
by ATPaS, GTPaS and CTPaS with veiy similar K; values and by UTPaS only 2 - 1 0  
fold more weakly and this was taken to imply that the ADP receptor shows little 
specificity for the adenine base. However, in the same paper ATPaS was said to be at 
least 40 - 80 fold more effective than these other nucleotide analogues at inhibiting 
functional responses to ADP which is consistent with previous reports (see section 1.6 of 
the General Introduction) and directly contradicts their assertion of low structural 
specificity. In view of the discrepancy between these binding affinities and the weak 
inhibitory effect of GTPaS, CTPaS and UTPaS on functional responses to ADP these 
binding sites probably do not represent functional ADP receptors. Thus, although there is 
increasing interest at the moment in the possibility that there may be nucleotide receptors 
which recognise both ATP and UTP (O'Connor et a l, 1991), and there has even been a 
suggestion that there may be specific pyrimidoceptors (Siefert & Schultz, 1989), the 
platelet ADP receptor appears to be a true purinoceptor, with a high degree of specificity 
towards the adenine base (see Haslam & Cusack, 1981; Hourani & Cusack, 1991 for 
review).
MeSATP inhibited ADP-induced increases in platelet cytosolic calcium concentration but 
in a non-competitive manner, and this is veiy similar to its effects on aggregation, as in 
each case the concentration-response curve to ADP in the presence of the inhibitor 
reached a plateau at about 60 - 70 % of the maximal effect in control experiments. 
Several 2-alkylthio analogues of ATP and AMP, including MeSATP, have been shown to 
be non-competitive but specific inhibitors of ADP-induced aggregation (these compounds
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showing no ability to inhibit aggregation induced by 11,9-epoxymethanoprostaglandin 
a thromboxane agonist), although their mechanism of action is unknown (Cusack & 
Hourani, 1982a; Hourani et al., 1986). Interestingly, MeSAMPPCP appeared to be a 
competitive antagonist of the effects of ADP on adenylate cyclase (Hourani et a l, 1986). 
Thus, in common with the agonists tested, the effects of MeSATP on ADP-induced 
increases in cytosolic calcium concentration agree well with its effects on ADP-induced 
aggregation, whilst the agreement between its effects on ADP-induced increases in 
cytosolic calcium concentration and those of MeSAMPPCP on inhibition by ADP of 
adenylate cyclase is veiy poor, again suggesting that these two second signalling 
responses to ADP are independent events.
For the six apparently competitive antagonists, the pA2  values obtained against 
ADP-induced increases in cytosolic calcium concentration in this study were in very good 
agreement with the pA2  values for the inhibition of ADP-induced aggregation reported by 
Cusack & Hourani (1982b) (or in the case of ATPPS also determined in this study) 
(correlation coefficient 0.976, p<0.01) (figure 2.8a). This confirms the conclusion that the 
above two events are causally related and that they are mediated by the same receptor and 
casts further doubt on the suggestion that FSBA can be used to label a platelet ADP 
receptor (Colman, 1992). FSBA has been reported to have no inhibitory effects on 
ADP-induced increases in cytosolic calcium concentration (Rao & Kowalski, 1987) an 
observation which was taken by these authors to imply that aggregation and shape change 
were mediated by a receptor which is distinct from that which induces increases in 
cytosolic calcium concentration. However, in the light of the results of the present study 
which show an extremely strong relationship between aggregation and increases in 
platelet calcium and the serious doubt which already exists over the specificity of the
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Figure 2.8 Comparison of the abilities of a number ATP analogues to inhibit responses 
to ADP. (a) Comparison of the pA2  values against aggregation and increases in cytosolic 
calcium concentration ([Ca2+];). (b) Comparison of the pAj values against increases in 
[Ca2+]i and inhibition of adenylate cyclase, (c) Comparison of the published pA  ^values 
against aggregation and inhibition of adenylate cyclase for the compounds shown in (b). 
The lines show the least squares regression fit to the data points. Compounds were: ATP 
(•), ATPaS (■), Cl-ATP (A), Ap5A (♦), AMPPCP (▼) and ATP|3S 00- For abbreviations, 
see text.
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effects of FSBA (see section 1.6.3 of the General Introduction) it can only be concluded 
that the protein labelled by FSBA (’aggregiri) is not an ADP receptor but represents a 
factor which is essential for the more distal events associated with platelet activation.
For the five antagonists reported here whose effects on inhibition by ADP of adenylate 
cyclase are known (the effects of ATPpS on this response have not been studied), the 
correlation between the reported pA2  values determined against inhibition of adenylate 
cyclase (Cusack & Hourani, 1982b) and those obtained in this study against ADP-induced 
increases in cytosolic calcium concentration was less good and did not quite reach 
significance at the 5 % level (correlation coefficient 0.826, 0.10>p>0.05) (figure 2.8b). 
However, if the published pAs values of these same 5 antagonists against aggregation and 
inhibition of adenylate cyclase (Cusack & Hourani, 1982b) are compared, the correlation 
is also not quite significant at the 5 % level (correlation coefficient 0.847, 0.10>p>0.05) 
(figure 2.8c), whilst when the 3 other antagonists used in the study of Cusack & Hourani 
are included the correlation is highly significant (p<0.01) (see Cusack & Hourani, 
1982b). This suggests that a larger number of antagonists would need to be studied before 
the significance of the correlation between these two parameters (antagonism of 
inhibition of adenylate cyclase and increases in cytosolic calcium concentration) can 
properly be evaluated.
In conclusion, these results show that there is an extremely good agreement between the 
effects of a number of ADP receptor agonists and antagonists on platelet cytosolic 
calcium concentration and platelet aggregation. This provides strong evidence that these 
two responses are mediated by the same receptor and provides further support for the idea 
that an increase in intracellular calcium concentration is the major signal for platelet
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aggregation induced by ADP.
CHAPTER 3 
STUDIES WITH SURAMIN
75
3.1 Introduction
It has recently been reported that the trypanocidal drug suramin (the structure of which is 
shown in figure 3.1) is a selective, competitive antagonist at P2X and P2Y receptors on 
vascular and visceral smooth muscle preparations, although it does not distinguish 
between these two receptor subtypes having a pA2  value of around 5 in each case (Den 
Hertog et al., 1989a, b; Dunn & Blakeley, 1988; Hoyle et al., 1990; Leff et al., 1990; Von 
Kiigelgen et al, 1990). Suramin also selectively inhibits the effects of ATP on PC 12 
phaeochromocytoma cells with a similar potency, the reported pA2  value being 4.5 (Inoue 
et a/., 1991; Nakazawa et al., 1990). As well as antagonizing P2 -purinoceptors, suramin is 
also known to inhibit a number of other proteins with nucleotide binding sites, for 
example yeast hexokinase (Wills & Wormall, 1950), erythrocyte membrane 
Na+/K+-ATPase (Fortes et al., 1973), firefly luciferase (Fortes et al., 1973), vacuole-type 
H+-ATPases (Calcaterra et al., 1988; Moriyama & Nelson, 1988), smooth muscle 
ectonucleotidases (Hourani & Chown, 1989), protein kinase C (Mahoney et al., 1990), 
mitochondrial adenine nucleotide exchanger (Calcaterra et a l, 1988), the GTPase activity 
associated with G; (Butler et al., 1988) and various polynucleotide synthesising enzymes 
(Broder et al., 1985; Offensperger et al., 1988; Ono et al., 1988). As the ADP receptor is 
classified as a P2-purinoceptor and acts as an ATP binding site (ATP being an antagonist 
at this receptor; Macfarlane & Mill, 1975), it was of interest to determine the effects of 
suramin on platelet responses to ADP. The effects of this compound on these various 
responses may also help to further resolve the debate as to whether there are one or two 
ADP receptors on platelets (see section 1.6.3 of the General Introduction) responsible for 
mediating these effects.
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Some of the data presented here have already been published (Hourani et al., 1992) and 
some have been reported as an abstract (Hall & Hourani, 1992), and copies of these 
papers are included at the back of this thesis.
Figure 3.1 The structure of suramin.
3.2 Materials and Methods
3.2.1 Materials
ADP, ATP, adrenaline, bacitracin, BSA, 11 a,9a-epoxymethanoprostaglandin H2  
(U46619), fibrinogen (fraction 1 from human plasma, essentially plasminogen free), 
fura-2-AM, 5-hydroxytryptamine creatinine sulphate complex (5-HT), 
isobutylmethylxanthine (IBMX), prostaglandin E, (PGE,), prostacyclin and triton X-100 
were from Sigma Chemical Company. AG50W-X8 [TP] was obtained from Bio Rad. 
[2,8-3 H]-cyclic AMP, ammonium salt (41.5 Ci/mmol) in 50 % aqueous ethanol and 
[U-1 4 C]-adenine (270 mCi/mmol) in 2 % aqueous ethanol were from Amersham 
International, pic. Suramin was a generous gift from Bayer, UK. All other chemicals were 
AnalaR grade from BDH. Prostacyclin was dissolved at 100 pg/ml in 10 mM NaOH, 
PGE, was dissolved at 1 mM in 50 % aqueous ethanol, U46619 was initially dissolved at 
30 mM in absolute ethanol then diluted to 10 mM with distilled water and fura-2-AM was
77
dissolved at 5 mM in dimethylsulphoxide. These solutions were stored at -20°C. IBMX 
was dissolved in HEPES-saline and all other drugs were dissolved in water. Adrenaline, 
bacitracin, fibrinogen, 5-HT, IBMX and suramin were made up fresh each day while the 
nucleotides were stored frozen.
3.2.2 Platelet Aggregation Studies
Venous blood was drawn from healthy human volunteers into one sixth of the volume of 
Acid-Citrate-Dextrose anticoagulant (25 g/1 tri-sodium citrate dihydrate, 15 g/1 citric acid 
monohydrate, 20 g/1 glucose) and centrifuged at 260 g for 20 min. Volunteers denied 
taking drugs for 10 days before the experiment. The PRP was removed and the platelets 
isolated by centrifugation at 680 g for 20 min in the presence of prostacyclin (1 juM) (to 
prevent activation). The supernatant plasma was discarded and the platelets resuspended 
at a density of 1 x 108/ml in HEPES-saline. Aggregation and shape change were followed 
photometrically (Bom, 1962a, b) with a Chrono-Log Lumi-Aggrometer, and aggregation 
was quantified as the maximal rate of change in light transmission (expressed as arbitrary 
units per min) through a stirred sample (0.5 ml) at 37°C on addition of agonist. Human 
fibrinogen (0.3 mg/ml) was added to all samples 20 sec before addition of agonist, and 
CaCl2  (1 mM) was added at the same time as suramin or at least 3 min before addition of 
the agonist. Suramin was added either simultaneously with the agonist or preincubated 
with the platelet suspension for various times at 37°C. The agonists used were ADP, 
U46619 and 5-HT. In the case of 5-HT, adrenaline (100 juM) was added simultaneously 
to potentiate its effects and result in a measurable aggregation response. Studies on the 
aggregation of platelets in plasma were performed as described in section 2 .2 .2 .
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EC5 0  values were obtained by regression analysis of the linear portion of the log 
concentration-response curves and dose ratios were calculated from the EC5 0  values 
obtained in the presence and absence of suramin. Where Schild analysis was not 
performed the apparent values for antagonists were calculated using the formula 
Kd = concentration of antagonist / (dose ratio - 1) and p ^  values were calculated as 
-log1 0 KD. Statistical significance was determined using Student’s t-test.
3.2.3 Calcium Measurement
Platelets were loaded with fura-2 as described in section 2.2.3. Aliquots of platelet 
suspension (0.7 ml; 1 x 108  platelets/ml) were incubated in siliconised glass aggregometer 
tubes at 37°C for 3 min in the presence of 1 mM CaCl2  and transferred to a Perkin-Elmer 
LS50 luminescence spectrometer for estimation of cytosolic calcium concentration. The 
stirred suspension was maintained at 37°C and excited with light at 380 nm. The emitted 
light intensity was measured at 510 nm. The fluorescence intensity at a saturating 
concentration of calcium ( F J  and in the absence of calcium (Fabs) were determined by 
lysing the platelets with 0.1 % triton X-100 (F^J followed by the sequential addition of 
20 mM tris and 10 mM EGTA. The cytosolic calcium concentration was then calculated 
using the equation [Ca2+] = KD (F-Fabs) / (F^-F) (Grynkiewicz et a l , 1985), where KD is 
the dissociation constant of the fura-2.calcium complex (225 nM). Suramin has a broad 
ultra-violet absorption spectrum and absorbs wavelengths up to 370 nm, it was therefore 
not possible to use the more usual dual wavelength method of calcium measurement with 
fura-2 as this requires excitation at around 340 nm. At 380 nm an increase in calcium 
concentration corresponds to a decrease in the fluorescence intensity of the dye (see 
figure 3.2). Agonists were added in 14 jul of water and suramin, where used, was added
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Figure 3.2 A typical fluorimeter trace from single wavelength calcium measurement. 
The trace shows the change in fluorescence intensity of a sample of fura-2-loaded 
platelets on addition of ADP (100 pM) (solid line) and a corresponding calibration 
spectrum (dashed line).
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simultaneously with the agonist. The response was quantified as the maximal change in 
cytosolic calcium concentration following addition of the agonist. The agonists used were 
ADP and 5-HT0adrenaline was not added with the 5-HT as a reliable response was 
obtained in its absence.
Log concentration-response curves were obtained at least three times using blood from 
different donors and the results were pooled. EC5 0  values were obtained by linear 
regression of the linear parts of the pooled log concentration-response curves and dose 
ratios were calculated from the EC5 0  values in the presence and absence of suramin.
3.2.4 Measurement of Inhibition of PGE}-stimulated Adenylate Cyclase
PRP (obtained as in section 3.2.2) was incubated with 4 pM [1 4 C]-adenine for 45 min at 
37°C. The platelets were then collected by centrifugation at 680 g for 20 min in the 
presence of prostacyclin (1 pM) (to prevent activation) and resuspended at 1.1 x 108/ml in 
HEPES-saline. Platelet cyclic AMP (cAMP) levels were determined by a modification of 
the method of Haslam & Rosson (1975). Aliquots (450 pi) of platelet suspension, which 
had been incubated for 3 min at 37°C in the presence of 1 mM CaCl2, were treated with 
solutions (50 pi) of ADP or adrenaline which contained PGEj (10 pM), to stimulate 
adenylate cyclase, IBMX (1 mM), to inhibit phosphodiesterase, and an appropriate 
concentration of suramin. After a further 30 second incubation at 37°C the reaction was 
terminated by addition of ice cold perchloric acid (100 pi; 3 M) containing [3 H]-cAMP 
(-20,000 dpm) to estimate recovery. After at least 30 min on ice the samples were 
centrifuged for 4 min in a microfuge and an aliquot (450 pi) of the supernatant applied to 
columns of AG50W-X8 [H+] (1.3 ml) to remove the adenine and adenosine. The cAMP
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peak was eluted with 1 mM KH^PC  ^ (pH 7.5) and the eluate was twice treated with 
nascent barium sulphate (by addition of 0.3 ml of 0.25 M zinc sulphate and 0.3 ml of 0.25 
M barium hydroxide) and centrifuged, to remove the adenine nucleotides other than 
cAMP. An aliquot ( 5 - 6  ml) of the supernatant was lyophilised and the 3H and 14C 
estimated by scintillation counting. 14C dpm were corrected for the recovery of 
[3 H]-cAMP, and the baseline level of [1 4 C]-cAMP (i.e. that in the presence of IBMX 
alone) was subtracted. Inhibition of adenylate cyclase was expressed as a percentage 
relative to the level of [1 4 C]-cAMP in platelets stimulated with PGEj alone. Log 
concentration-response curves were obtained in platelets from at least three different 
donors in triplicate and pooled. The EC5 0  values were calculated by linear regression of 
the linear portion of the pooled log concentration-response curves. Dose ratios were 
calculated from these EC5 0  values.
Concentration-response curves to PGE} were performed in a similar manner to above, but 
in the absence of ADP or adrenaline, and the results were expressed in dpm as 
[1 4 C]-cAMP present in the platelet suspension, corrected for the baseline effects of 
IBMX. These experiments were carried in the presence of a constant concentration of 
ethanol corresponding to that present at the highest concentration of PGEj assayed.
3.3 Results
In citrated human plasma, ADP induced platelet aggregation with an EC5 0  value of 1.1 
pM, and this aggregation was inhibited in an apparently competitive manner by 
simultaneous addition of ATP (40 pM), with a pA^> value of 5.00. Suramin (100 juM) 
added simultaneously with ADP had no effect on ADP-induced aggregation or on the
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inhibition of this aggregation by ATP (figure 3.3a). Preincubation with suramin (100 pM) 
for 40 min at 37°C did not inhibit ADP-induced aggregation (figure 3.3b) even in the 
presence of the non-selective peptidase inhibitor bacitracin (2 mg/ml) (figure 3.3c). 
Suramin alone did not cause shape change or aggregation at concentrations up to 1 mM 
(data not shown).
In washed platelets, ADP induced aggregation with an EC5 0  value of 4.3 pM, and suramin 
added simultaneously with ADP caused dose-dependent, parallel, rightward shifts of the 
log concentration-response curve (figure 3.4a). Schild analysis of these data gave a slope 
of 1.82 ± 0.21, which was significantly greater than unity (p<0.05), and an apparent pA2  
value (the negative log of the concentration causing a dose-ratio 2) of 4.62 (figure 3.4b). 
Under these conditions ATP also caused dose related, parallel, rightward shifts of the log 
concentration-response curve for ADP, but gave a Schild plot slope of 0.96 ±0.16 and a 
pA2  value of 4.74 (figure 3.4b). Incubation of washed platelets with suramin for 10 or 40 
min at 37°C before addition of ADP also yielded Schild plots with slopes significantly 
greater than unity (2 . 0 1  ± 0.16 and 2.06 ± 0 .0 1 , respectively), and with increasing time of 
incubation there was a reduction in the potency of suramin (apparent pA2  values of 4.43 
and 4.05 after 10 and 40 min, respectively) (figure 3.5). For this reason all subsequent 
studies using suramin were performed with suramin added simultaneously with the 
agonist.
Washed platelet aggregation induced by U46619 or by 5-HT (in the presence of 100 juM 
adrenaline) was also inhibited by suramin at concentrations of 200 or 400 pM, but this 
inhibition was not competitive and suramin caused a marked reduction in the maximal 
response to these agonists. ATP (100 pM) also reduced the maximal response to U46619,
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Figure 3.3 Aggregation of human platelets in plasma induced by ADP alone (•) or in the 
presence of suramin (100 pM) (O), ATP (40 pM) (■) or both ATP (40 pM) an<i suramin 
(100 pM) (□). (a) Antagonists added simultaneously with ADP. (b) Platelets preincubated 
with suramin for 40 min before addition of ADP. (c) Platelets incubated in the presence 
of bacitracin (2 mg/ml) and suramin or vehicle for 40 min before addition of ADP. Each 
point is the mean of 3 determinations, and vertical bars show the s.e. mean.
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Figure 3.4 The effect of suramin on washed platelet aggregation induced by ADP. (a) 
Effect of ADP alone (O) (n = 10) or in the presence of suramin at 50 pM (•) (n = 10), 100 
pM (■) (n = 10), 150 pM (A) (n = 3), 200 pM ^ )  (n = 10) or 400 pM (▼) (n = 6 ). Each 
point is the mean of 3 - 10 determinations (as shown in the brackets), and vertical bars 
show the s.e. mean, (b) Schild plot of the data presented in (a) (•), and an equivalent 
Schild plot for the antagonism of ADP-induced washed platelet aggregation by ATP (■).
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Figure 3.5 Schild plots obtained when washed platelets were preincubated for 0 (•) (as 
shown in figure 3.4), 10 p )  or 40 min (▲) before addition of ADP.
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the effect being similar to 200 pM suramin, but did not affect aggregation induced by 
5-HT (figure 3.6).
ADP also induced concentration-dependent increases in platelet cytosolic calcium 
concentration with an EC5 0  value of 1.0 pM. This effect of ADP was inhibited by suramin 
which caused dose-dependent, rightward shifts of the log-concentration response curve to 
ADP (figure 3.7a). Schild analysis of these data gave a slope of 2.3 ± 0.3, which was 
significantly greater than unity (p<0.05) and an apparent p ^  value of 4.63 (figure 3.7b). 
Suramin (100 - 400 pM) was also able to inhibit increases in platelet cytosolic calcium 
concentration induced by 5-HT although this inhibition was not competitive as suramin 
caused a decrease in the maximal response to this agonist and the effect was limited as 
200 and 400 juM suramin caused similar levels of inhibition (figure 3.8). Suramin alone 
did not affect the fluorescence of the platelet suspension and therefore had no effect on 
the basal cytosolic calcium concentration at any concentration tested.
PGE^stimulated cAMP accumulation was concentration-dependently inhibited by ADP, 
giving an EC5 0  value of 0.47 pM. Suramin inhibited this effect of ADP in a 
concentration-dependent manner (figure 3.9a) and Schild analysis of this inhibition 
resulted in a slope of 1.00 ± 0.10 and a value of 5.09 (figure 3.9b). Suramin had no 
effect on the inhibition of stimulated adenylate cyclase by adrenaline (figure 3.10), but 
was able to inhibit accumulation of cAMP induced by sub-maximal concentrations of 
PGEj, causing a 4 fold shift to the right of the log concentration-response curve (figure 
3.11). Suramin alone (400 pM) had no significant effect on the basal level of cAMP in 
platelets (289 ± 34 dpm (n = 7) in the absence of suramin, 292 ±41 dpm (n = 3) in its 
presence) or on the effect of PGE} (1 pM) in the experiments measuring inhibition by
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Figure 3.6 Aggregation of washed platelets induced by (a) U46619 or (b) 5-HT (in the 
presence of 1 0 0  pM adrenaline) alone (•) or in the presence of suramin ( 2 0 0  pM (■) or 
400 juM (A)) or ATP (100 pM) (#). Each point is the mean of 3 determinations, and 
vertical bars show the s.e. mean.
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Figure 3.7 Effects of suramin on increases in platelet cytosolic calcium concentration 
([Ca2+];) induced by ADP. (a) Increases in platelet [Ca2+]; induced by ADP in the absence 
(•) or presence of suramin at 50 pM (■), 80 pM (A), 130 pM ($) or 200 pM (f). Each 
point is the mean of three separate determinations on platelets from different donors, and 
vertical bars show the s.e. mean, (b) Schild plot of the data presented in (a) (•) and the 
Schild plot of inhibition by ATP of this response (taken from figure 2.2) (dashed line).
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Figure 3.8 Effects of suramin on increases in platelet cytosolic calcium concentration 
([Ca2 +]j) induced by 5-HT. Increases in [Ca2+]j induced by 5-HT in the absence (•) or 
presence of suramin at 100 pM (■), 200 pM (A) or 400 pM (♦). Each point is the mean of 
three determinations on blood from different donors, and vertical bars show the s.e. 
mean.
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Figure 3.9 Effects of suramin on the inhibition of PGE,-stimulated cAMP accumulation 
by ADP. (a) Inhibition of PGEj-stimulated cAMP accumulation by ADP in the absence 
(•) or presence of suramin at 50 pM (■), 100 pM (▲), 200 pM ($) or 400 pM (▼). Each 
point is the mean of at least 3 determinations on platelets from different donors, and 
vertical bars show the s.e. mean, (b) Schild plot of the data presented in (a).
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Figure 3.10 Inhibition of PGEr stimulated cAMP accumulation by adrenaline in the 
absence (•) or presence (♦) of suramin (400 pM). Each point is the mean of at least 3 
determinations on platelets from different donors, and vertical bars show the s.e. mean.
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Figure 3.11 A representative graph showing the accumulation of cAMP in human 
platelets induced by PGEj in the absence (•) or presence (■) of suramin (400 juM). Each 
point is the mean of triplicate determinations, and vertical bars show the s.e. mean.
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ADP or adrenaline (933 ± 128 dpm (n = 7) in the absence of suramin, 897 ±117 dpm 
(n = 7) in its presence).
3.4 Discussion
In this study suramin was able to antagonize ADP-induced aggregation of human platelets 
in buffer but had no effect on platelets in plasma. The lack of effect of suramin in plasma 
was not likely to be due to degradation of the antagonist by plasma enzymes, as varying 
the incubation time between 0 and 40 min even in the presence of the peptidase inhibitor 
bacitracin did not affect the results. Indeed, in pharmacokinetic studies in vivo suramin 
has been shown not to be significantly metabolized, however it did bind non-specifically 
and with high capacity to plasma proteins, with greater than 99 % of the drug being 
protein-bound at equilibrium (Collins et al., 1986). It is likely therefore that the lack of 
effect of suramin on platelets in plasma is due to its rapid binding to plasma proteins.
In washed platelets, suramin antagonized the aggregation of human platelets induced by 
ADP in an apparently competitive manner, causing parallel, dose-dependent, rightward 
shifts of the log concentration-response curve to ADP without decreasing the maximal 
response (where full log concentration-response curves were obtained). However, Schild 
analysis of this inhibition revealed that suramin was not acting as a pure competitive 
antagonist as the slope of the Schild plot was around 2. In a detailed study of the 
antagonism by suramin of the effects of ATP on P2x-purinoceptors in the rabbit ear artery, 
Leff et al. (1990) also reported a Schild plot slope significantly greater than unity and 
attributed this to slow equilibration of suramin with the receptors, as increasing the 
incubation times for low concentrations of suramin reduced the Schild plot slope to unity. 
From an analysis of the time-dependence of the inhibitory effects of suramin, Leff et al
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(1990) concluded that very long incubation times, up to 220 min, were necessary to reach 
equilibrium at low concentrations. However, in platelets slow equilibration is unlikely to 
be the explanation for the steep Schild plot slope as increasing the incubation time from 0 
to 40 min (incubation times longer than 40 min could not be used because responses to 
ADP could not be reliably obtained) did not affect the slope of the Schild plot but merely 
reduced the potency of the antagonist, possibly due to slow binding of suramin to the 
BSA which was routinely included in the assay buffer. In addition, in a stirred suspension 
of platelets access of suramin to the receptors is likely to be more rapid and complete 
than in a smooth muscle preparation, and long incubation times are not necessary to 
obtain Schild plot slopes of unity with other antagonists in PRP (Cusack & Hourani, 
1982b).
Suramin also caused a concentration-dependent inhibition of ADP-induced increases in 
platelet cytosolic calcium concentration and again the slope of the Schild plot for this 
inhibition was significantly greater than unity. Interestingly, the Schild plot slope 
obtained for the inhibition by suramin of this response, 2.3 ± 0.3, was very similar to that 
obtained for its inhibition of platelet aggregation, 1.82 ± 0 .2 1 , as was the apparent pAs 
value, these being 4.63 and 4.62, respectively. In chapter 2, it was shown that there is a 
very strong correlation between the ability of a number of ADP receptor antagonists to 
inhibit ADP-induced aggregation and their ability to inhibit ADP-induced increases in 
cytosolic calcium concentration. However, the compounds used in this study were all 
analogues of ATP and were therefore all structurally quite similar to ADP. Suramin is 
structurally unrelated to these compounds and yet still shows an extremely good 
agreement between its effects on these two responses to ADP. This observation further 
strengthens the evidence for the suggestion, made in Chapter 2, that these two effects of
ADP are mediated by the same receptor.
Suramin also acted as an antagonist of the inhibition by ADP of PGEj-stimulated 
adenylate cyclase activity. However, in this case Schild analysis resulted in a slope of 
unity, suggesting that the effect was competitive, the pA  ^value being 5.09 (corresponding 
to an apparent KD value of 8 .1 juM). Suramin (400 jliM) did not reduce the ability of 
adrenaline (which was used here as a control agonist in preference to 5-HT which has 
little effect on platelet adenylate cyclase activity) to inhibit stimulated adenylate cyclase 
activity. However, suramin did inhibit the accumulation of cAMP induced by PGEj, 
although at the concentration of PGEj used in the inhibition assays (1 juM, which is close 
to being maximally effective) the effect of 400 pM suramin was insignificant (when 
measured in parallel control assays in these experiments). The inhibition of the effect of 
PGEj by suramin appears to be competitive, in that the log-concentration curves are 
parallel and the maximal response is not decreased. However, suramin was somewhat 
less potent at inhibiting the effect of PGEj than responses to ADP, 400 pM suramin 
causing only a 4 fold shift in the log concentration-response curve to PGEj. This 
concentration of suramin caused an approximately 1 0 0  fold shift in the log 
concentration-response curve for ADP-induced aggregation and an approximately 40 fold 
shift in the log concentration-response curve for inhibition by ADP of stimulated cyclase 
activity. Interestingly, both ADP and PGEj are negatively charged in solution at 
physiological pH and this may be taken to imply the presence of positively charged 
regions in their respective receptor binding sites to pair with these negative charges. In 
early studies with suramin as an enzyme inhibitor (Wills & Wormall, 1950) it was 
suggested that this compound has its inhibitory effects by binding to positively charged
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regions of these proteins. As ADP is a more highly charged molecule than PGEj 
(possessing a diphosphate chain compared to a single carboxylate group) this binding of 
suramin to positive charges could be used to explain the relative potencies of suramin 
against these two agonists, the ADP receptor contains a larger positively charged region 
and would therefore bind suramin more strongly. These data may therefore suggest that 
suramin acts as an antagonist at the platelet P2T receptor, as it does at smooth muscle P2X 
and P2Y receptors, by charge pairing with positively charged amino acid residues in or 
near to the nucleotide binding site. However, it also has various non-specific inhibitory 
effects (it can also non-competitively inhibit responses to 5-HT and U46619, this will be 
discussed further below) possibly due to its ability to bind to positively charged regions of 
other proteins on the platelet surface.
In the cases of ADP-induced aggregation and increases in cytosolic calcium 
concentration, inhibition by suramin resulted in Schild plot slopes significantly greater 
than unity. Possible explanations of a Schild plot slope greater than unity are that the 
antagonist is not in equilibrium with the receptor population, that more than one 
molecule of antagonist is binding to the receptor, that it is acting non-competitively, that 
the antagonist is acting on a heterogeneous population of receptors or that it is having 
multiple effects on the response (Kenakin, 1993). As discussed earlier, the antagonist not 
being at equilibrium with the receptors is unlikely to be the explanation of the steep 
Schild plot slope in this study as increasing the incubation time from 0 to 40 min did not 
decrease the slope of the Schild plot, as would be expected if this were the case. A Schild 
plot slope near 2  could imply that on average 2  molecules of suramin must bind to the 
receptor to cause its inhibitory effect, but although from our results it is not possible to 
draw firm conclusions about the stoichiometry of the interaction, there is no evidence that
any other ADP antagonist exhibits multiple binding interactions (Cusack & Hourani, 
1982b). However, the symmetrical ('dimeric') nature of the suramin molecule may confer 
different binding characteristics from those of previously tested ADP antagonists, which 
were all analogues of AMP and ATP. The third possibility, that suramin is acting as a 
non-competitive antagonist, cannot be ruled out, however the log concentration-response 
curves to ADP were shifted to the right with no apparent depression of the maximal 
response, at least at concentrations of suramin for which full concentration-response 
curves could be obtained, suggesting against this.
The fourth possibility, that there are multiple ADP receptors, has been suggested by 
Colman and co-workers (1980; see also Colman, 1992), although this suggestion (as has 
already been pointed out in section 1.5.3 of the General Introduction) is not consistent 
with results from antagonist studies (Cusack & Hourani, 1982b). In any case, of the two 
receptors proposed in this model only one is thought to mediate aggregation, the other 
being proposed to mediate the inhibition of adenylate cyclase. From the results of the 
study presented here, if there are indeed two ADP receptors on platelets then both are 
responsible for mediating aggregation (and indeed for mediating increases in cytosolic 
calcium concentration), although as suramin gave a Schild plot slope of unity for 
inhibition of the effects of ADP in adenylate cyclase this may imply that only one of these 
putative receptors mediates this response. This could suggest that the ion-channel 
mediated (calcium influx) and G-protein mediated (mobilization of intracellular calcium 
and inhibition of adenylate cyclase) responses to ADP are in fact caused by distinct 
receptors. This would also explain the apparent non-competitive inhibitory effects of the 
2-alkylthio-analogues of ATP and AMP on aggregation and increases in intracellular 
calcium concentration. From the results described for MeSAMPPCP on inhibition of
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adenylate cyclase (Hourani et al., 1986) these compounds appear to behave as 
competitive antagonists of the putative G-protein coupled receptor. If, however, this class 
of compounds do not inhibit the putative ion-channel coupled receptor, it would explain 
the observation that these compounds cannot completely inhibit aggregation (Cusack & 
Hourani, 1982a) but inhibit this response by a maximum of only about 50 %. Further this 
could explain the lack of inhibitory effect of MeSAMPPCP on responses to ADPaS. 
ADPaS is a partial agonist of aggregation (Cusack & Hourani, 1981b) and increases in 
cytosolic calcium concentration (see Chapter 2 of this thesis), whilst it is an antagonist of 
the effects of ADP on adenylate cyclase (Cusack & Hourani, 1981b). As in this model 
MeSAMPPCP only acts at the putative G-protein coupled receptor, at which ADPaS is 
also an antagonist, but not at the putative ion-channel coupled receptor, at which ADPaS 
is an agonist, MeSAMPPCP would not be expected to show any inhibition of responses to 
this compound. This hypothesis could be tested using the analogues ADPaS and 
MeSATP. If ADPaS is indeed only an agonist at the putative ion-channel coupled 
receptor it should not induce increases in intracellular calcium concentration when this 
response is measured in the absence of extracellular calcium. Also, if MeSATP is a 
competitive antagonist of the putative G-protein coupled receptor then in the absence of 
extracellular calcium this antagonist should show competitive antagonism of 
ADP-induced increases in intracellular calcium concentration. However, again this model 
is not consistent with the data obtained with other antagonists which showed no 
suggestion of multiple receptor sites mediating aggregation and which showed a good 
correlation between the ability of these antagonists to inhibit the effects of ADP on 
aggregation and adenylate cyclase (Cusack & Hourani, 1982b).
99
However, suramin clearly did have non-specific effects in addition to its antagonism of 
ADP, as it non-competitively inhibited aggregation induced by U46619 and 5-HT, which 
act at thromboxane ('TP') and 5-HT2  receptors, respectively, on platelets (Hourani & 
Cusack, 1991). Also suramin non-competitively inhibits the effects of 5-HT on platelet 
cytosolic calcium levels. Given its avid binding to protein molecules it is possible that, at 
high concentrations, suramin may interact with platelet surface proteins and in some way 
interfere with the pathways by which platelets increase their cytosolic calcium 
concentration in response to aggregating agents. The fifth explanation, that suramin is 
having multiple effects on the response to ADP is, therefore, the most likely. Although 
ATP at high concentrations also non-competitively inhibited aggregation induced by 
U46619 this is probably due to its inhibition of the effects of released ADP, as ATP did 
not inhibit aggregation induced by 5-HT which is a weaker aggregating agent and does 
not induce the release of stored nucleotides from platelets. Indeed to achieve aggregations 
to 5-HT it was necessary to potentiate its effects with a fixed concentration of adrenaline, 
as either of these agonists alone did not induce reliable aggregations.
Although the pA2  values for suramin obtained against ADP-induced aggregation and 
increases in intracellular calcium in this study have to be treated with caution because of 
the steep Schild plot slopes and consequent uncertainty as to the mechanism of action of 
suramin, these pA2  values and the pA2  value obtained against inhibition by ADP of 
stimulated adenylate cyclase activity do correspond well with those obtained in other 
studies. As an antagonist of the effects of ADP on adenylate cyclase, where suramin 
appeared to behave competitively, the pA2  value was 5.09 which is close to the values 
ranging from 4.5 to 5.4 which have been reported for inhibition of the effects of ATP on 
smooth muscle preparations and phaeochromocytoma cells (Hoyle et ah, 1990; Inoue et
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a l, 1991; Leff et al., 1990; Von Kugelgen et a l, 1990). The apparent pA  ^values obtained 
for suramin against ADP-induced platelet aggregation and increases in cytosolic calcium 
concentration of 4.62 and 4.63, respectively, are also well within this range. In those 
cases in which no pA2  value has been reported, the concentrations of suramin which have 
shown an inhibitory effect against ATP are generally in the micromolar range, and are 
also therefore consistent with these values (Den Hertog et a l , 1989a, b; Hoiting et a l , 
1990). The similarity of the pA2  values found for the inhibition of platelet responses to 
ADP and for antagonism of ATP on other tissues, suggests that the ADP receptor is 
indeed similar to P2-purinoceptors elsewhere, and that suramin is unable to distinguish 
between the sub-types of P2 -purinoceptor. The concentrations of suramin required for 
antagonism at P2-purinoceptors are similar to the IC5 0  or K; values reported for inhibition 
by suramin of the various enzymes which bind purine nucleotides, which are also 
generally in the micromolar range (Wills & Wormall, 1950; Fortes et a l , 1973; Butler et 
al, 1988; Calcaterra et a l, 1988; Moriyama & Nelson, 1988; Ono et a l, 1988; Mahoney 
et a l, 1990), suggesting that these binding sites may be structurally related.
In conclusion, the results presented here show that suramin is an antagonist of platelet 
responses to ADP, although it is not effective in plasma, it is not specific for ADP and in 
the case of aggregation and increases in cytosolic calcium concentration it is not simply 
competitive. The pA2  values are consistent with the values found for P2-purinoceptors 
elsewhere, showing that although it is unique in that ATP is an antagonist rather than an 
agonist, the platelet ADP receptor is indeed a type of P2 -purinoceptor.
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CHAPTER 4
EFFECTS OF EXTRACELLULAR 
DIVALENT CATION 
CONCENTRATION
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4.1 Introduction
In physiological buffers, and indeed in biological fluids e.g. plasma, ATP exists as a 
mixture of several species including divalent cation complexes, Mg. ATP2' and Ca.ATP2', 
and the tetrabasic form, ATP4*. It is now widely accepted that the P2Z receptor responds to 
this tetrabasic form of ATP rather than any of the other species of ATP found in solution 
(Cockcroft & Gomperts, 1979). Evidence is also accumulating that the preferred agonist 
at other ATP receptors is this tetrabasic form of ATP rather than, for example, the 
magnesium complex which acts as a substrate of ecto-ATPases (Pearson et a l, 1980) and 
is well known as the substrate of kinase enzymes. For example it has been suggested that 
ATP4* is the agonist species at the P2X receptor on the guinea-pig vas deferens (Fedan et 
a l, 1990) and that ATP4* and UTP4* are the agonists at the P2Y and P2U receptors present 
on aortic endothelial cells (Motte et a l, 1993). It would seem therefore that a 
characteristic of ATP receptors is that they require the uncomplexed form of ATP and do 
not recognise the divalent cation complexes, whilst the opposite is true of ATP 
phosphotransferase enzymes. This may have implications as to the conformational 
requirements of these proteins for the triphosphate chain of ATP. There are presumably 
conformations of the triphosphate chain which are not accessible when it is bound to 
magnesium, one of these conformations is therefore likely to be the ligand for the 
P2 -purinoceptors. Similarly, there are conformations of the triphosphate chain which are 
more favourable in the presence of magnesium and it is one of these conformations which 
acts as the substrate for the phosphotransferases (Eckstein, 1985; Frey, 1992).
Although platelets do not aggregate in the absence of divalent cations, due to the 
dissociation of the Gp Eb-IIIa complex (Peerschke, 1985), they are still able to undergo a
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shape change response. This would suggest that extracellular divalent cations are not 
required for the binding of ADP to the ADP receptor or for the production of this 
response. Also, 2-azido-ADP and MeSADP have both been shown to bind to platelets in 
the absence of divalent cations (Macfarlane et a l , 1982; 1983) further suggesting that 
extracellular divalent cations are not required for the binding of ADP to its receptor. 
However, the divalent cation requirement of the response of platelets to ADP has never 
been studied in detail and it is not known whether the ADP receptor responds to all ADP 
species or simply to the uncomplexed form of ADP, ADP3*. Similarly it is not known 
which form (or forms) of ATP (divalent cation complexes, ATP4*) acts as the antagonist 
at this receptor. In this study the effects of varying the extracellular concentration of 
magnesium and calcium was determined on the ability of ADP to activate platelets. Two 
responses of platelets to ADP were studied, shape change and inhibition of adenylate 
cyclase, both of which occur in the absence of extracellular calcium. ADP-induced 
platelet shape change, however, is thought to be triggered by the increase in cytosolic 
calcium concentration induced by this agonist (see section 1.4 of the General 
Introduction). This increase in cytosolic calcium concentration is, in part, caused by 
influx of calcium into the platelet from the extracellular medium (Hallam & Rink, 1985a; 
Sage & Rink, 1986) and removal of extracellular calcium may therefore attenuate this 
response. The effect of extracellular divalent cation concentration was, therefore, also 
determined on the ability of ADP to inhibit PGE^stimulated adenylate cyclase activity, as 
this response does not appear to be due to the increase in cytosolic calcium concentration, 
but seems to occur via an independent, G-protein mediated pathway (see Chapter 2 of this 
thesis).
As changes in the potency of an agonist may reflect changes in both the affinity of the
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agonist for the receptor and its efficacy in inducing the response, the effects of varying 
the extracellular divalent cation concentration were also determined on the ability of ATP 
to antagonize these ADP receptor mediated responses. The effects of a competitive 
antagonist are only dependent upon its affinity for the receptor and thus the effects of 
divalent cation concentration on antagonism of the ADP receptor by ATP may help to 
clarify the effects of these manipulations on responses to ADP.
4.2 Materials and Methods
4.2.1 Materials
ADP, ATP, BSA, IBMX, PGEl 5  prostacyclin and tetrabutylammonium hydrogen sulphate 
were obtained from Sigma. AG50W-X8 [H+] was from Bio Rad. [2,8-3 H]cAMP (41.5 
Ci/mmol) in 50 % aqueous ethanol and [U-1 4 C]-adenine (270 mCi/mmol) in 2 % ethanol 
were from Amersham International. HPLC solvents were from Fisons, all other chemicals 
were AnalaR grade from BDH. PGEj was dissolved at 1 mM in 50 % aqueous ethanol 
and prostacyclin was dissolved at 100 pg/ml in 10 mM NaOH. Both compounds were 
stored in solution at -20°C. IBMX was dissolved in nominally divalent cation-free 
HEPES-saline and nucleotides were dissolved in water. IBMX was made up freshly each 
day whilst nucleotides were stored frozen.
4.2.2 Measurement of Platelet Shape Change
Blood was drawn from healthy human volunteers into one sixth of the volume of 
Acid-Citrate-Dextrose anticoagulant and centrifuged at 260 g for 20 min to obtain PRP. 
Donors denied taking drugs for 10 days before the experiment. Platelets were obtained by
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centrifuging the PRP at 680 g for 20 min in the presence of prostacyclin (1 juM). The 
supernatant plasma was discarded and the platelets were suspended in 1 0  ml of nominally 
divalent cation-free HEPES-saline (145 mM NaCl, 5 mM KC1, 10 mM glucose, 10 
HEPES, 2 mg/ml BSA adjusted to pH 7.4 with NaOH 1M). The platelets were again 
collected by centrifugation at 680 g for 20 min in the presence of prostacyclin (1 pM) and 
resuspended at 1 x 108/ml in nominally divalent cation-free HEPES-saline. The second 
centrifugation step was employed to help to remove residual plasma proteins which may 
allow the platelets to aggregate during shape change measurement.
Aliquots (0.3 ml) of platelet suspension were incubated in siliconised glass aggregometer 
tubes at 37°C for 3 min in the presence of 1 mM MgCl2, 1 mM CaCl2, both 1 mM MgCl2  
and 1 mM CaCl2, 1 mM EGTA or an equivalent volume of water and transferred to a 
Chrono-Log Lumi-Aggrometer. Shape change was quantified as the maximal decrease (in 
arbitrary units) in light transmission through the stirred sample at 37°C on addition of the 
agonist, relative to a 50 % dilution of the platelet suspension (i.e. 5 x 107  platelets/ml). 
Diluted platelet suspension was used as the reference rather than HEPES-saline to 
magnify the responses. Under the above conditions, i.e. in the absence of fibrinogen (and 
other plasma proteins), aggregation in response to ADP is negligible as measured in the 
aggregometer.
ADP was added in 6  pi of water and ATP, where used, were added simultaneously with 
the ADP. Log concentration-response curves were obtained in triplicate in blood obtained 
from at least 3 donors. EC5 0  values were obtained by regression analysis of the linear 
portion of the triplicate concentration-response curves and dose ratios for antagonists 
were determined from the EC5 0  values in the presence and absence of the ATP. The
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apparent KD values for ATP were obtained from the dose ratios using the formula 
Kd = concentration of ATP / (dose ratio - 1) and pA^ values were calculated as -log1 0 KD. 
Statistical significance was determined by analysis of variance or, when only two sets of 
conditions were compared, Students t-test.
4.2.3 Measurement of Inhibition of PGEj-stimulated Adenylate Cyclase
Inhibition of PGEj-stimulated adenylate cyclase activity was measured as described in 
section 3.2.4 with the following modifications. Platelets were suspended at 1.1 x 108/ml 
in nominally divalent cation-free HEPES-saline which was supplemented with either 
MgCl2  (1 mM) and CaCl2  (1 mM) or EGTA (1 mM) during the 3 min preincubation at 
37°C before addition of agonist solutions. Log concentration-response curves were 
obtained in triplicate in blood from at least three donors and presented as [1 4 C]-cAMP 
dpm in the sample corrected for recovery. EC5 0  values were obtained by regression 
analysis of the linear portion of these concentration-response curves. Dose ratios for ATP 
were determined from the EC5 0  values in the presence and absence of ATP and apparent 
Kd values were calculated using the formula KD = concentration of ATP / (dose ratio - 1). 
Statistical significance was determined using Student's t-test.
4.2.4 Determination of Nucleotide Release from Platelets
Platelets were resuspended at 1 x 108/ml in nominally divalent cation-free HEPES-saline 
and aliquots (1.8 ml) were incubated at 37°C in the presence of either 1 mM MgCl2  and 1 
mM CaCl2  or 1 mM EGTA. After 3.5 min, aliquots (0.5 ml) were removed and layered 
onto a mixture of silicone oils (4 parts Dow Coming 704 EU diffusion pump fluid and 
1 part Dow Coming 200/0.65 cs silicone fluid) (200 pi). The platelets were separated
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from the suspending medium by centrifugation in a swing out microfuge for 1  min and 
aliquots (300 - 400 pi) of the supernatant were removed and stored at -20°C before HPLC 
analysis. The concentration of ADP released from the platelets was determined by HPLC 
(using methanol as the solvent in buffer B) as described in section 2.2.5.
4.2.5 Calculation of Free ADP3- and ATP4' Concentrations
In solutions containing only a single divalent cation species (i.e. Mg2+ or Ca2+ alone) the 
free ADP3* or ATP4* concentration was calculated using the method of Dahlquist & 
Diamant (1974) by solving the following quadratic equation:
KJAXP ] 2  + [AXP]/Km[M]t  - Km[AXP]t + 1 ) - [AXP]T = 0
where,
M represents either Ca2+ or Mg2+,
AXP represents either ADP or ATP,
Km is the stability constant of the M.AXP complex (logKM = 2.80 for Ca.ADP, 
3.30 for Mg.ADP, 3.94 for Ca.ATP and 4.28 for Mg.ATP: Taqui Kahn & Martell, 
1966; 1967),
[AXP]f is the concentration of free ADP3- or ATP 4%
[AXP]t is the total concentration of AXP, and 
[M]t is the total concentration of M.
In solutions containing both 1 mM calcium and 1 mM magnesium the [AXP]f was 
approximated as the mean of the [AXP]f calculated in the presence of 2 mM calcium and
in the presence/2 mM magnesium. No adjustment was made to the free divalent cationK
concentration when determining [AXP]f in solutions containing both ADP and ATP, as
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the change due to the presence of the other nucleotide would not exceed - 1 0  % even at 
the highest concentrations used (i.e. in solutions containing 100 pM ATP and 100 pM 
ADP).
4.3 Results
ADP induced platelet shape change in a concentration-dependent manner under all 
conditions tested (figures 4.1 & 4.2). The pD2  values (-log1 0 EC50) obtained for ADP were 
not significantly different (p<0.05) under the various conditions tested (the pD2  values 
under these various conditions are shown in table 4.1). However, there did appear to be a 
slight decrease in the maximal response to ADP in the absence of added divalent cations 
and in the presence of EGTA (figure 4.2c). This shape change was inhibited by ATP in all 
cases (figures 4.1 & 4.2a & b), although this inhibition by ATP was significantly greater 
in the presence of EGTA and in the absence of added divalent cations than in the 
presence of divalent cations (p<0.05) (the pA2  values for ATP under these conditions are 
also shown in table 4.1). This increase in pA2  value shows an 18.2 fold increase in the 
affinity (apparent KD) of ATP for the ADP receptor in the presence of EGTA compared to 
the presence of both calcium and magnesium.
ADP also inhibited PGEr induced accumulation of cAMP by platelets both in the 
presence of divalent cations and in the presence of 1 mM EGTA, however, in this case 
there was a significant leftward shift in the log concentration-response curve in the 
absence of divalent cations (figure 4.3). The pD2  values were 6.48 ± 0.10 in the presence 
of divalent cations (EC5 0  = 0.33 pM) and 7.21 ± 0.24 in the presence of EGTA 
(EC50= 0.07 pM) (p<0.05). Again ATP inhibited the response to ADP and this inhibition
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Figure 4.1 Shape change induced by ADP alone (filled symbols) or in the presence of 
ATP ( 1 0 0  jliM )  (open symbols), in the presence of (a) 1  mM MgCl2  and 1  mM CaCl2  
(• ,o ) , (b) 1 mM CaCl2  alone (■,□) or (c) 1 mM MgCl2  alone (A ,A). Each point is the 
mean of 3 triplicate determinations on platelets from different donors, and vertical bars 
show the s.e. mean.
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Figure 4.2 Shape change induced by ADP alone (filled symbols) or in the presence of 
ATP ( 1 0 0  j jM )  (open symbols) (a) in the absence of added divalent cations (# ,0 )  or (b) 
in the presence of 1 mM EGTA (^V ). Each point is the mean of 3 triplicate 
determinations, and vertical bars show the s.e. mean, (c) A comparison of the data shown 
in figures 4.1 and 4.2a & b. Symbols are as previously stated, error bars have been 
omitted for clarity.
I l l
Conditions pD2  for ADP pA  ^for ATP pD2  for ADP3* pA2  for ATP4*
1 mMMgCLj + 1 mM CaCl2 6.42 ± 0.07 4.88 ±0.11 6.97 ±0.06 6.31 ±0.06
1 mM CaCl2 6.67 ±0.12 5.42 ±0.16 6.90 ±0.11 6.38 ±0.16
1  mMMgCl2 6.59 ±0.14 5.36 ±0.16 6.99 ±0.16 6.72 ±0.16
No added divalent cations 6.55 ±0.10 6.13 ±0.20 6.70 ±0.10 6.31 ±0.14
1 mM EGTA 6.60 ± 0.05 6.14 ±0.14 6.71 ±0.10 6.37 ±0.16
Table 4.1 The pD2  values for the induction of platelet shape change by ADP and ADP3' 
and the pA  ^values for its inhibition by ATP and ATP4-. Values are the mean ± s.e. mean 
of three determinations on platelets from different donors.
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Figure 4.3 Inhibition of PGEr stimulated cAMP accumulation by ADP alone ( •  ,▼) or in 
the presence of ATP (100 pM) (0 ,V). Experiments were performed in the presence of 
1 mM CaCI2  and 1 mM MgCl2  (# , 0 ) or in the presence of 1 mM EGTA (▼,V). 
Unconnected symbols show the levels of cAMP in platelets incubated in the absence 
(• ,□ ) or presence of PGEj (#,Y) in the presence of divalent cations (• ,■ ) or EGTA 
(▼,□). The data are representative of 3 similar experiments, each point is the mean of 
triplicate or quadruplicate (controls) determinations, and vertical bars show the s.e. mean.
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was significantly greater in the absence of divalent cations than in their presence, the pA  ^
values being 6.59 ± 0.26 and 5.24 ± 0.05, respectively (p<0.01). This gives an 
approximately 22 fold increase in the apparent affinity of ATP for the receptor in the 
presence of EGTA.
Interestingly, along with its inhibition of the effect of ADP, ATP also seemed to enhance 
the ability of PGEj to stimulate adenylate cyclase in the presence of EGTA. In the 
presence of divalent cations the accumulation of cAMP induced by PGEj was similar in 
the presence or absence of ATP (100 juM) (5578.8 ± 54 dpm (n = 4) in its absence
5522.5 ± 193 dpm (n = 3) in its presence). However, incubation of platelets with 0.5 
units/ml apyrase (a concentration which completely inhibited aggregation induced by 
1 pM ADP in PRP) could also enhance the PGEr stimulated accumulation of cAMP. In 
the presence of EGTA both ATP (100 pM) and apyrase caused a slight increase in the 
cAMP accumulation induced by PGEj. The levels of cAMP were 4854.9 ±195 dpm 
(n = 3) for PGEj alone, 5318.8 ± 354.1 dpm (n = 3) in the presence of apyrase and 
5216.7 ± 101 dpm in the presence of ATP, however, neither of these increases was 
significant. Similarly, in the presence of divalent cations there was a slight, but not quite 
significant, increase in the amount of cAMP accumulated in the presence of apyrase 
(6076.5 ± 285.4 dpm (n = 3)) compared with its absence (5578 ± 54 dpm (n = 4)). Also, 
in the presence of EGTA ATP (100 pM) caused no significant accumulation of cAMP in 
the absence of PGEj, the basal level of cAMP in platelets was 562 ± 136.4 dpm (n = 4) in 
the absence of ATP and 547.9 ±110 dpm (n = 3) in presence of ATP (100 pM). In HPLC 
studies, platelets released significantly more ADP, 1.39 ± 0.11 pM (n = 3), in the 
presence of EGTA than in the presence of divalent cations, 1.12 ± 0.11 pM ADP (n = 3),
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(p<0.05).
Figures 4.4 and 4.5 show the data presented so far in this study in terms of the 
concentration of ADP3' present rather than in terms of the total ADP concentration. 
Again, in the shape change experiments ADP shows no significant difference in potency 
in inducing the response in the presence or absence of divalent cations (see table 4.1). In 
the experiments on the inhibition of adenylate cyclase when the ADP concentration is 
presented in terms of free ADP3' the pD2  values are no longer significantly different, the 
values being 6.98 ± 0.10 and 7.21 ± 0.24 in the presence of calcium and magnesium or 
EGTA, respectively. Also when the pA2  values for inhibition of these responses by ATP 
are determined using the concentration of free ATP4* present rather than the total ATP 
concentration these values are no longer significantly different when measured for either 
response. The pA2  values for ATP4- from the shape change data are summarised in table 
4.1, from the adenylate cyclase inhibition experiments the p ^  values for ATP4' were 
6.64 ± 0.03 in the presence of divalent cations and 6.59 ± 0.26 in the presence of EGTA.
4.4 Discussion
These data suggest that the platelet ADP receptor does not recognise all of the species of 
ADP present in solution as agonists but that only ADP3', the free ionic form of ADP, is 
able to act as an agonist at this receptor. Similarly it would appear that it is ATP4* which 
acts as the antagonist at this receptor rather than other ATP species.
In the presence of 1 mM calcium and 1 mM magnesium the concentration of ATP4' 
present in solution is approximately 4 % of the total ATP concentration. This is, 
therefore, approximately 25 fold less than the concentration present in the absence of
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Figure 4.4 This figure shows the data presented in figure 4.2c but in terms of the ADP3* 
concentration. Symbols are as previously stated, curves in the presence of ATP and error 
bars have been omitted for clarity.
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Figure 4.5 This figure shows the data presented in figure 4.3 in terms of ADP3' 
concentration. Symbols are as previously described.
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these divalent cations, which has been assumed to be 100 % of the total ATP present 
(although, of course, this is an over-estimate as, for example, the second ionizable 
hydroxyl of the y-phosphate will be protonated to some extent at physiological pH). Thus 
if ATP4-, rather than all forms of ATP, were the active antagonist at the ADP receptor a 
25 fold increase in the affinity of ATP would be expected in the absence of divalent 
cations. The observed increases in affinity of ATP for the ADP receptor in the absence of 
divalent cations, of 18.2 and 22.3 in the shape change and adenylate cyclase inhibition 
experiments respectively, compare very well, therefore, with this predicted value.
In a solution of ADP containing 1 mM of these two divalent cations, however, 
approximately 30 % of the ADP is present as ADP3-, and therefore only a 3.3 fold 
leftward shift in the log concentration-response curve to ADP would be expected in the 
absence of divalent cations. In the experiments measuring inhibition of PGEr stimulated 
adenylate cyclase by ADP, there was indeed a small, but significant, leftward shift in the 
log concentration-response curve, giving a potency ratio of 5.5, which is also close to that 
predicted from the change in the concentration of ADP3- present in the solution in the 
absence and presence of divalent cations.
In the case of shape change the EC5 0  values for ADP in the presence and absence of 
divalent cations were not significantly different and the observed potency ratio of 1.5 is 
only about half of the expected value of 3.3. However, the log concentration-response 
curves in the presence and absence of divalent cations are somewhat differently shaped. 
The curves in the absence of divalent cations show a lower maximal response and are 
rather flatter than those in their presence, suggesting that the removal of extracellular 
divalent cations interferes with this response in some way. Interestingly, it is only in the
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absence of both divalent cations that this depression of the maximal response is seen 
rather than simply in the absence of calcium, suggesting that calcium influx is not 
required for shape change but that mobilization of intracellular calcium is sufficient to 
produce a maximal response. This observation also suggests that some extracellular 
factor which requires divalent cations (either calcium or magnesium) for functional 
integrity is necessary to produce a maximal shape change in response to ADP. An 
obvious candidate for this role would be glycoprotein Ilb-IHa which is known to require 
divalent cations for its association and which is essential for aggregation in response to 
ADP.
Another possible explanation for the decreased maximal response in the absence of 
divalent cations is desensitization of the ADP receptor by the endogenous ADP released 
by the platelets when they are kept in buffer, there being more ADP released in the 
presence of EGTA than in the presence of divalent cations. However, if this were due to 
desensitization, it might be expected that the depression of the maximal response would 
be accompanied by a rightward shift in the concentration-response curve, and even if this 
rightward shift were not seen the curves should be superimposed when expressed as 
percentages of the maximal response. When expressed in this way the curves were not 
superimposed (figure 4.6a), indeed the curve in the presence of EGTA was shifted to the 
left (see below), suggesting that desensitization is not a satisfactory explanation for this 
reduction in the maximal response.
The differing maxima of the log concentration-response curve for induction of shape 
change makes the comparison of the EC5 0  values from these curves unreliable as an index 
of changing potency. However, when the shape change data in the presence of divalent
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Figure 4.6 Shape change induced by ADP in the presence of 1 mM CaCl2  and 1 mM 
MgCl2  (•) or 1 mM EGTA (▼) calculated as % maximal response, (a) Data presented 
against the total ADP concentration, (b) Data presented in terms of the concentration of 
ADP3-. Each point is the mean of 3 triplicate determinations in blood from different 
donors, vertical bars show the s.e. mean.
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cations and in the presence of EGTA are normalized to percentages of the response to 
30 pM ADP (figure 4.6) the curves are comparable and a significant difference between 
the pD2  values for ADP is seen under these two sets of conditions, the pD2  values being 
6.43 ± 0.06 (EC5 0  -  0.37 pM) in the presence of divalent cations and 6 . 8 8  ± 0.03 
(EC5 0  = 0.14 pM) in the presence of EGTA (p<0.01). There is, therefore, a 2.6 fold 
increase in the potency of ADP in the absence of divalent cations which again agrees very 
well with the ratio of 3.3 expected if ADP3' is in fact the agonist. Indeed when the data 
are presented in terms of the concentration of ADP3- the log concentration-response 
curves are almost superimposed (figure 4.6b) and there is no significant difference 
between the pD2  values, which are 6.96 ± 0.07 and 6 . 8 8  ± 0.03, respectively, further 
suggesting that the ADP receptor is in fact an ADP3- receptor.
In the results from the studies on the inhibition by ADP of PGEj-stimulated adenylate 
cyclase it was noticeable that, in the absence of divalent cations, ATP not only inhibited 
the effects of ADP but also appeared to enhance the ability of PGEj to stimulate 
adenylate cyclase. There has recently been a suggestion that ATP, as well as acting as a 
competitive antagonist at the ADP receptor, is able to stimulate platelet adenylate cyclase 
via a P2X-like receptor (Soslau & Parker, 1989; Soslau et al., 1993). However, washed 
platelets are known to release adenine nucleotides into the suspending medium (Mustard 
et al., 1989) and this apparent stimulation of adenylate cyclase by ATP may, therefore, 
represent the reversal of the inhibitory effects of released ADP rather than a separate 
effect of ATP mediated by a distinct purinoceptor subtype on these cells. In the present 
study washed platelets did indeed release ADP and, in fact, released slightly more ADP in 
the presence of EGTA than they did in the presence of divalent cations. Thus in the
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absence of divalent cations, when the apparent stimulation of adenylate cyclase by ATP is 
most pronounced, platelets not only release more ADP, which will cause a greater basal 
level of inhibition of this enzyme, but a greater proportion of this ADP will be in the 
active form (ADP3*) and a greater proportion of the added ATP will be present as the 
active antagonist (ATP4*). Thus if the apparent stimulation of adenylate cyclase by ATP is 
actually due to its inhibition of the effects of released ADP, the ATP would be expected 
to show the most marked effect in the presence of EGTA, as indeed it does.
When platelets were exposed to PGEj in the presence of apyrase, which will breakdown 
the released ADP to AMP, the increase in cAMP was slightly greater than that in the 
absence of apyrase. Although the increase with either apyrase or ATP did not quite reach 
significance at the 5 % level there was a trend in the effect of both towards a potentiation 
of the effect of PGEj. Thus, the breakdown of released ADP has the same effect as the 
presence of ATP on the response to PGEj suggesting that this effect of ATP is simply due 
to reversal of the inhibition by released ADP of the response to PGEj. More importantly, 
when platelets were exposed to ATP in the absence of PGEj (in the presence of EGTA, 
when ATP had its greatest apparent stimulatory effect) the basal level of cAMP as not 
significantly different from that in the presence of IBMX alone, further suggesting that 
the effect of ATP is not to increase cAMP itself but simply to antagonize competitively 
the effects of released ADP.
In the study by Soslau et a l (1993) it was suggested that the ability of ATP to inhibit 
aggregation by U46619 and collagen was due to this apparent ability of ATP to increase 
platelet cAMP levels. However, both of these aggregating agents are known to cause the 
release of ADP from platelet dense-granules (Siess, 1989), this released ADP potentiating
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the response to the primary agonist. The inhibition of aggregation induced by U46619 and 
collagen is, therefore, attributable to the ability of ATP to inhibit the effects of released 
ADP. The putative ATP receptor in this study was apparently desensitized by 
pre-incubation in the presence of AMPCPP for up to 120 min, the ability of ATP to 
inhibit aggregation induced by U46619 and collagen decreasing with increasing time of 
incubation. The inhibition of ADP-induced aggregation by ATP remained relatively 
constant over this period of time. However, platelets become refractory to ADP when 
stored in the absence of ADP scavenging systems (e.g. apyrase or creatine 
phosphate/creatine kinase) due to the release of ADP, whilst they are still able to respond 
to other aggregating agents. Because of this gradual reduction in the platelet response to 
ADP, the relative contribution that released ADP will make to the response to these other 
aggregating agents will also decrease with time. Thus ATP would be expected to show a 
reduced level of non-competitive inhibition of the response to other agonists simply due 
to the reduced contribution to the response made by released ADP. The results of this 
study are therefore entirely explicable in terms of previously characterised responses of 
platelets and a separate ATP receptor need not be postulated. Also these authors did not 
show the effect of this incubation period on their control responses thus it was not 
possible to see if there was a reduction in the responses to U46619 or collagen simply due 
to the incubation period.
One important technical criticism of these studies (Soslau & Parker, 1989; Soslau et a l, 
1993) is that in their studies on adenylate cyclase they claim to have terminated their 
assays by addition of 4 mM EDTA (which will simply chelate extracellular divalent 
cations) followed by centrifugation to sediment the platelets. However, the results of the 
study presented here show that adenylate cyclase activity is not inhibited by chelation of
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extracellular divalent cations. This must cast further doubt on the results from these
studies.
In conclusion, the data presented in this chapter suggest that the platelet ADP receptor is 
in fact an ADP3’ receptor, binding only this form of ADP as its agonist. Similarly, the 
receptor only appears to recognise ATP4- as an antagonist. Thus in common with other 
P2-purinoceptors the platelet ADP receptor appears to recognise the free ionic form of its 
ligands rather than the divalent cation complexes. ATP also appears to potentiate the 
accumulation of cAMP by platelets induced by PGEj. However, this potentiation is 
probably due to the reversal of the inhibitory effects of ADP released by platelets when 
suspended in buffer rather than to any independent effect of ATP.
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CHAPTER 5 
BINDING STUDIES
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5.1 Introduction
A number of studies have been performed on the binding of radiolabelled ADP to human 
platelets and these have been carried out under a wide range of experimental conditions, 
for example on intact platelets both in citrated plasma and in buffer and on platelet 
membrane preparations (e.g. Bom, 1965; Salzman et a!., 1966; Nachman & Ferris, 1974; 
Bom & Feinberg, 1975; Bauvois et al., 1980; Lips et a l, 1980). These authors reported 
receptor densities ranging from 30,000 to 100,000 sites per platelet, with affinities in the 
low micromolar range (for review see Haslam & Cusack, 1981). However, these studies 
suffered from a number of technical difficulties, for example, rapid metabolism of the 
radioligand to other species (ATP, AMP and adenosine) which will have different binding 
constants and in the case of adenosine will bind to a distinct receptor site and be taken up 
into the platelet cytosol. Platelets suspended in citrated plasma release ADP from their 
dense granules in response to exogenous ADP causing isotopic dilution. Also, the 
platelets will change shape in response to the ADP (and indeed aggregate in citrated 
plasma) potentially making the estimation of the non-specific binding difficult due to 
changes in the extracellular space when centrifugation assays are employed. 
Interpretation of the data from binding studies on platelet membranes will also be 
complicated by the exposure of irrelevant nucleotide binding sites on the inner leaflet of 
the plasma membrane and on other intracellular membranes (see Haslam & Cusack, 
1981; Siess, 1989; Hourani & Cusack, 1991).
The most convincing studies so far performed on intact, functional platelets used the 
2-substituted ADP analogues 2-azido-ADP (N3 -ADP) and MeSADP labelled with 32P on 
the (3-phosphate (Macfarlane et al., 1982; 1983). These studies were performed on
126
platelets suspended in EDTA-plasma and on washed platelets suspended in calcium-free 
buffer. These authors showed that both of these analogues bound to a single class of 
binding site, N3-ADP binding to approximately 500 sites per platelet with an affinity of 
134 nM in plasma and 17.5 nM in buffer and MeSADP binding to approximately 750 
sites per platelet with an affinity of 14.7 nM in plasma and 5.7 nM in buffer. The binding 
of both of these analogues was displaced by ADP and ATP with Kj values in the low 
micromolar range, by AMP at least 100 fold more weakly than ADP or ATP and by IDP 
and GDP at least 20 fold more weakly. These values are consistent with the effects of 
these compounds in functional studies (Macfarlane & Mills, 1975; Packham et a l, 1972; 
Packham et al., 1974). The binding of MeSADP was displaced by N3 -ADP. In a later 
study by Cristalli and Mills (1993) the binding of MeSADP was also shown to be 
displaced by ATPaS and ADPpS. ATPaS was equipotent with ATP which is consistent 
with the effects of these two compounds on the inhibition by ADP of adenylate cyclase 
(Cusack & Hourani, 1982b) and indeed the K; values obtained by Cristalli & Mills 
(around 4pM) correspond very well with the KB values obtained by Cusack & Hourani 
(4.6 pM for ATPaS and 6.2 pM for ATP). ADPpS was a slightly better displacer of 
MeSADP than ADP, although as these compounds are both agonists it is difficult to relate 
differences in their affinity obtained from binding studies to differences in potency 
obtained in functional studies.
In the study by Macfarlane et al. (1983), the binding of MeSADP was also displaced by 
the sulphydryl reagent ^ -mercuribenzene sulphonate (pMBS), a compound which blocks 
the ability of ADP to inhibit adenylate cyclase but which does not inhibit shape change 
induced by this compound (Mills & Macfarlane, 1977; Macfarlane & Mills, 1981), but
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was not displaced by FSBA (Mills et a l , 1985) which inhibits shape change and 
aggregation but not the effects of ADP on adenylate cyclase (Colman, 1992). This was 
taken by these authors as evidence that these two compounds bind to the ADP receptor 
which causes inhibition of adenylate cyclase. However, Rao & Kowalski (1987) showed 
that whilst pMBS had no effect on ADP-induced shape change, it did inhibit increases in 
platelet cytosolic calcium concentration. However, even at 1 mM, pMBS did not 
completely inhibit increases in cytosolic calcium concentration induced by ADP and the 
increase in cytosolic calcium concentration which occurred in its presence may still have 
been sufficient to induce an unaltered shape change. Sensitivity to pMBS but not FSBA 
does not, therefore, imply that the MeSADP binding site on platelets only mediates the 
inhibition of adenylate cyclase as pMBS can inhibit both of the second messenger effects 
of ADP (inhibition of adenylate cyclase and increases in cytosolic calcium concentration) 
and there is some doubt whether FSBA labels a functional ADP receptor at all. Also both 
N3-ADP and MeSADP are potent aggregating agents as well as inhibitors of adenylate 
cyclase, thus the binding of both of these compounds to only a single site on the platelet 
surface would suggest that there is in fact only a single receptor responsible for these two 
responses to ADP.
More recently a number of binding studies have been performed on formaldehyde-fixed 
platelets (Jefferson et a l, 1988; Agarwal et a l, 1989; Greco et a l, 1991; 1992) using 
[3 H]-ADP and the antagonist [3 5 S]-ATPaS as radioligands. Formaldehyde-fixed platelets 
were used to remove the complications of rapid metabolism of the radioligand by 
platelets and isotopic dilution by released ADP (Jefferson et a l, 1988), however, as these 
authors themselves state the major drawback of the use of fixed platelets is that the 
fixation process will cause chemical modifications of the binding sites which may affect
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ligand accessibility. Indeed, if enzymes on the platelet surface are modified in such a way 
that they no longer possess catalytic activity it is not unreasonable to assume that similar 
marked changes will occur in the binding sites of other nucleotide-binding proteins 
treated in this manner including the ADP receptor. These binding studies show both high 
and low affinity binding sites for ADP and ATPaS which are mutually accessible to these 
ligands, platelets showing around 30,000 high affinity sites and 300,000 low affinity sites 
with dissociation constants of 30 nM and 3 j l iM  for ADP and 3 nM and 200 nM for 
ATPaS, respectively. However, the structure-activity relationships for these binding sites 
are not entirely consistent with the known pharmacology of the ADP receptor, for 
example guanosine and pyrimidine nucleotide analogues bind to these binding sites with 
similar affinities to ATPaS whilst being at least 50 fold less potent than this compound as 
inhibitors of ADP induced shape change, and indeed the results of the two most recent of 
these reports (Greco et a l , 1991; 1992) show that these binding sites are on the 
glycoprotein Ilb-IIIa complex. In the 1991 study ATPaS was used in an attempt to 
covalently label the ADP receptor. A single 120 kDa polypeptide was labelled and this 
was shown to be identical to glycoprotein lib. This labelling was greatly reduced in the 
presence of EDTA, which dissociates the Gp Ilb-HIa complex, suggesting that the 
nucleotide binding site is formed within the Gp Ilb-IIIa complex. This is supported by the 
observation that the photoaffinity reagent 8 -azido-ATP labelled both glycoprotein lib and 
m a (Mayinger & Gawaz, 1992). These ADP/ATPaS binding sites are unlikely to 
represent the ADP receptor, however, as individuals with Glanzmanris thrombasthenia, 
whose platelets lack both of these glycoproteins (Phillips & Agin, 1977), are still able to 
respond to ADP (e.g. Zucker et a l 1966; Powling & Hardistry, 1985).
129
A number of other attempts have been made to identify the ADP receptor by covalent 
labelling. An attempt was made to use N3-ADP as a photoaffinity reagent for the ADP 
receptor and this molecule did label a number of sites on the platelet surface, however, 
this labelling was not prevented by ADP (Macfarlane et a l , 1982) suggesting that none of 
these proteins represent the ADP receptor. More recently the photoaffinity reagent 
2-azidophenylethylthio-ADP was used in an attempt to label the ADP receptor identified 
in binding studies with MeSADP and N3-ADP and this compound was found to label a 
single 43 kDa polypeptide (Cristalli 8c Mills, 1993). This labelling was prevented by a 
number of ADP receptor ligands (both agonists and antagonists) in a manner which was 
reasonably consistent with the pharmacology of the ADP receptor although there were 
some discrepancies, e.g. ATP was - 1 0  fold better at preventing this labelling than 
ATPaS, whilst ATPaS is at least 5 fold better than ATP as an antagonist of responses to 
ADP (Cusack & Hourani, 1982b; Chapter 2 of this thesis). This polypeptide is probably 
the best candidate so far for the ADP receptor.
A 61 kDa ADP binding protein was extracted from freeze-thawed platelet membranes by 
washing with isotonic saline (Adler & Handin, 1979). This protein bound ADP with a 
dissociation constant of 0.38 pM and bound ADP was displaced by ADP and ATP with 
similar potencies, at least 1000 fold more weakly by AMP and not at all by adenosine 
which is consistent with the pharmacology of the ADP receptor. However, it seems 
unlikely that a receptor protein would be so easily extracted from the plasma membrane 
and, indeed, no further work on this protein has been published. FSBA labels the 100 kDa 
protein 'aggregin' (Colman, 1992) but as discussed in the General Introduction this is also 
unlikely to represent an ADP receptor.
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In this study, the binding of [3 5 S]-Sp-ATPaS to intact, washed platelets was investigated 
along with the ability of a number of ATP analogues, which are known to act as ADP 
receptor antagonists, to displace this binding. Antagonists were used in this study to avoid 
the complicating effects associated with the use of agonists (see earlier). Also as the 
compounds used in this study were all ATP analogues and the predominant enzyme 
activity associated with platelets is nucleoside diphosphokinase (Guccione et a l , 1971), 
which phosphorylates ADP to ATP, breakdown of these compounds should not present a 
problem in this study. An ATP regenerating system (pyruvate kinase and 
phosphoenolpyruvate) was included in the binding experiments to guard further against 
ligand breakdown.
5.2 Materials and Methods
5.2.1 Materials
AMPCPP, AMPPCP, Ap5 A, ATP, BSA, CTP, FSBA, GTP, phosphoenolpyruvate, 
prostacyclin, pyruvate kinase (type III from rabbit muscle), tetrabutylammonium 
hydrogen sulphate and UTP were from Sigma. Cl-ATP, ketanserin, MeSATP, NECA and 
yohimbine were obtained from Research Biochemicals Incorporated. Unlabeled ATPaS 
was obtained initially from Boehringer Mannheim or subsequently from Calbiochem (for 
reasons of cost). [3 5 S]-SP-ATPaS (>1000 Ci/mmol) in 10 mM tricine buffer, pH 7.6, 
containing 1 mM dithiothreitol was obtained from NEN. For use in time course 
experiments the specific activity was adjusted to 2 Ci/mmol (on the reference date) with 
unlabelled ATPaS. For use in displacement experiments the specific activity was 
adjusted to 10 Ci/mmol (on the reference date) with unlabelled ATPaS. HPLC solvents
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and scintillation fluid, Optiphase, were from Fisons Scientific Apparatus. Suramin was a 
generous gift from Bayer, U.K. All other chemicals were AnalaR grade from BDH. 
Where necessary nucleotides were purified by ion-exchange chromatography as described 
in section 2.2.6. Prostacyclin was dissolved at 100 pg/ml in 10 mM NaOH and stored 
frozen in aliquots, FSBA was dissolved at 50 mM in dimethylformamide and diluted to 
10 mM in water and other drugs were dissolved in water. FSBA, ketanserin, suramin and 
yohimbine were made up freshly each day, nucleotides were stored frozen in solution.
5.2.2 Preparation of Washed Platelets
Blood was drawn from healthy human volunteers into one sixth of the volume of ACD 
anticoagulant. Donors denied taking aspirin for 10 days before the experiment. PRP was 
obtained by centrifuging the blood at 260 g for 20 min. The platelets were isolated from 
the PRP by centrifugation (680 g for 20 min) in the presence of prostacyclin (1 pM) and 
resuspended in 2 ml of HEPES-saline (see section 2.2.3) containing phosphoenolpyruvate 
(100 pM) and pyruvate kinase (5 units/ml) and an aliquot (10 pi) was diluted 50 fold in 
1 % ammonium oxalate for counting on a haemocytometer. The platelet suspension was 
then made up to between 30 and 60 ml with HEPES-saline containing 
phosphoenolpyruvate (100 pM) and pyruvate kinase (5 units/ml). This resulted in a 
platelet count between 1.5 and 3.0 x 108 /ml.
5.2.3 Time Course of ATPaS Binding
For association time courses, platelets were incubated at room temperature for various 
times in the presence of 1 pM [3 5 S]-ATPaS (2 Ci/mmol). Non-specific binding was 
determined in parallel experiments in the presence of 100 pM unlabelled ATPaS. At
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appropriate times triplicate aliquots (0.5 ml) of platelet suspension were removed and 
bound radioactivity was determined as described in section 5.2.5 below.
For dissociation time courses, platelets were incubated at room temperature in the 
presence of 1 pM [3 5 S]-ATPaS for 40 min at which point 100 pM unlabelled ATPaS was 
added to displace the bound radioligand. Parallel estimates of the non-specific binding 
were performed by adding 100 pM unlabelled ATPaS simultaneously with the 
radioligand. Bound radioactivity was determined as described in section 5.2.5 below.
5.2.4 Displacement Studies
Aliquots (1.8 ml) of platelet suspension were incubated at room temperature in the 
presence of 60 nM [3 5 S]-ATPaS (10 Ci/mmol) and various concentrations of displacing 
ligand. After 40 min triplicate 0.5 ml aliquots of suspension were removed and the bound 
radioactivity quantified as described in section 5.2.5 below.
Due to the high concentrations of radioligand which would be necessary to saturate the 
receptor population and the correspondingly high concentrations of displacing ligand 
which would be necessary to define the non-specific binding, saturation experiments 
could not be used to determine the binding parameters of ATPaS. The results of an 
attempted saturation experiment are shown in figure 5.1. The dissociation constants of 
ATPaS and number of ATPaS binding sites were, therefore, determined by Scatchard 
analysis of homologous displacement curves. Heterologous displacement curves were 
analysed by weighted non-linear curve fitting algorithms using the LIGAND program.
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Figure 5.1 The binding of ATPaS to platelets using a saturation protocol. The figure 
shows a representative data for the total (■), non-specific (•) and specific (4) ATPaS 
binding to washed platelets. Values are the mean of triplicate determinations and the 
vertical bars show the s.e. mean. Non-specific binding was determined in the presence of 
1 mM ATP.
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5.2.5 Determination of Bound Radioactivity
Aliquots (0.5 ml) of platelet suspension were layered onto silicone oil (4 parts Dow 
Coming 704 EU diffusion pump fluid and 1 part Dow Coming 200/0.65 cs silicone fluid) 
and centrifuged for 1  min in a swing out microfuge to separate the platelets from the 
suspending medium. An aliquot (10 pi) of the supernatant buffer was transferred to a 
scintillation vial for counting. The remaining buffer and silicone oil were removed and 
the pellets washed three times by gentle immersion in 0.9 % NaCl (to avoid resuspending 
the platelets). The tubes were inverted to allow any residual saline to drain. After ~30 min 
the tip of the tube, containing the pellet, was cut off and transferred to a scintillation vial. 
The bound radioactivity was extracted over night in 5 ml of Optiphase and 0.4 ml of 1 % 
triton X-100 after an initial vortex mixing. The tubes were then vortex mixed and the 
radioactivity present quantified by scintillation counting. The dpm present in the 
supernatant were used to calculate the specific activity of the radioligand used in the 
experiment.
5.2.6 HPLC analysis
HPLC analysis of aliquots of the supernatant from the binding assays (performed in the 
absence of radioligand) to determine the release of adenine nucleotides from platelets and 
the degradation of adenine nucleotide analogues by platelets were performed as described 
in Chapter 2 section 2.2.5.
5.3 Results
Binding studies were performed in the absence of added calcium (but in the presence of
135
magnesium) as preliminary studies showed that the binding was stable for a longer period 
in its absence (see figure 5.2). The binding of [3 5 S]-ATPaS was essentially at equilibrium 
after 30 min incubation and remained stable for at least another 30 min under the assay 
conditions (figure 5.2b). Thus an incubation time of 40 min was chosen for the 
displacement assays to ensure binding equilibrium had been reached. This binding was 
rapidly reversible returning to the level of non-specific binding within 1 0  min of addition 
of a large excess of unlabelled ligand (figure 5.2c).
Homologous displacement studies showed that the binding of ATPaS was best described 
by a two site binding model (figure 5.3). The level of non-specific binding in the 
displacement assays never exceeded 50 % of the total radioactivity bound and never 
exceeded 0.08 % of the total radioactivity added to an assay. There were 1668 ±316 
(n = 4) high affinity sites with a dissociation constant of 0.21 pM (pKD = 6.69 ± 0.08) and 
24184 ± 9988 (n = 4) low affinity sites with a dissociation constant of 32 pM (pKD = 4.50 
± 0.28). Binding to the high affinity site was displaced by ATP, MeSATP, Cl-ATP, 
AMPCPP, AMPPCP, Ap5A and suramin (figure 5.4) and the values for this 
displacement are summarised in table 5.1. ATP, MeSATP & Cl-ATP were also able to 
displace ATPaS from the low affinity binding sites and the Kj values for this 
displacement are again shown in table 5.1. In the case of AMPCPP, AMPPCP and Ap5 A, 
it was not possible to define a K; at the low affinity site as the affinities of these 
compounds at this site were too low. Consequently the affinity at the high affinity site for 
these compounds was defined using a one site displacement model. The displacement of 
[3 5 S]-ATPaS binding by suramin followed a much steeper curve than that of the other 
displacing ligands and appeared to reach a plateau at a level greater than that of
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Figure 5.2 Kinetics of the binding of [3 5 S]-ATPaS to washed human platelets, (a) Time 
course of the binding of [3 5 S]-ATPaS to platelets in the presence of 1 mM Ca2+. (b) Time 
course of the binding of [3 5 S]-ATPaS to human platelets in the absence of added calcium, 
(c) Time course of the displacement of bound [3 5 S]-ATPaS from platelet by addition of 
an excess of unlabelled ATPaS. The data are representative of three similar experiments.
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Figure 5.3 (a) Homologous ATPaS displacement isotherm (oo on the abscissa represents 
the level of non-specific binding). The data are representative of 5 similar experiments. 
Values are the mean of triplicate determinations and vertical bars show the s.e. mean, (b) 
Scatchard plot of the data presented in (a).
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Figure 5.4 Displacement of [3 5 S]-ATPaS by a number of ADP receptor antagonists, 
(a) ATPaS (•) and Ap5A (o ), (b) ATP (■) and suramin (□), (c) Cl-ATP (A) and MeSATP 
(A), and (d) AMPCPP (▼) and AMPPCP (v ). Values are the mean of three separate 
determinations using blood from different donors and vertical bars show the s.e. mean.
139
Ligand n PKH KH(pM) PKL KL(pM)
ATP 5 6.47 ±0.12 0.34 4.07 ±0.31 85.1
MeSATP 3 6.70 ±0.26 0 . 2 4.76 ±0.40 17.6
Cl-ATP 3 7.58 ±0.11 0.03 5.67 ±0.20 2 . 1
AMPCPP 3 5.41 ± 0.08 3.9 n.d. n.d.
AMPPCP 3 3.90 ±0.20 126 n.d. n.d.
ApsA 3 4.01 ±0.11 97 n.d. n.d.
Suramin 3 4.42 ±0.08* 63.6* - -
*Due to the steep displacement curve for suramin pIC5 0  and IC^ values are shown.
Table 5.1 The K* values of ADP receptor antagonists for the displacement of 
[3 5 S]-ATPaS from high affinity (KH) and low affinity (KL) binding sites on human 
platelets. Values are the mean ± s.e. mean of three separate determinations on blood from 
different donors. (n.d. = not determined, - = did not displace).
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non-specific binding suggesting that it could not displace the radioligand from the low
affinity binding site. Due to this steep displacement curve IC5 0  rather than K; values are
quoted for suramin in table 5.1 as satisfactory analysis of these data by LIGAND to give
values was not possible. The binding of ATPaS was not displaced by NECA (100
pM), ketanserin (1 pM), yohimbine (10 pM), FSBA (100 pM) (relative to an appropriate
solvent control) or UTP (100 pM), but 46.4 ± 1.6 % of the specifically bound radioligand
was displaced by GTP (100 pM) and 11 ±3.7 % was displaced by CTP (100 pM) (see 
figure 5.5).
HPLC studies showed that none of the adenine nucleotide analogues used in this study 
were detectably broken down under the conditions of these binding assays at 100 pM 
(results not shown). However, adenine nucleotides were released by the platelets and this 
resulted in approximately 2 pM ATP being present during the assays (figure 5.6). The 
amount of ATP present in a given experiment appeared to be constant throughout its 
duration as the total binding measured in control assays performed at the beginning and 
end of a binding experiment were not significantly different. The presence of this ATP 
should not affect the apparent affinity of the displacing ligands determined in these 
studies, however, it will result in a marked underestimation of the number of the high 
affinity sites available to the radioligand. Using the binding constants obtained here the 
presence of 2 pM ATP would result in a 5.5 fold under estimation of the number of high 
affinity binding sites suggesting that there may in fact be -9000 high affinity sites. The 
estimation of the number of low affinity sites should not be affected due to the much 
lower affinity of ATP at this site.
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Figure 5.5 Displacement of [3 5 S]-ATPaS by dimethylformamide (DMF) (0.5 %), FSBA 
(100 pM), NECA (100 pM), ketanserin (1 pM), yohimbine (10 pM), UTP (100 pM), 
CTP (100 pM) and GTP (100 pM). Values are the mean of three separate determinations 
using blood from different donors and vertical bars show the s.e. mean. (** = p<0.05, 
++ = not significantly different from control in the presence of DMF).
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Figure 5.6 (a) An HPLC trace showing the ATP released from platelets into the 
suspending medium under the conditions of a binding experiment, the radioligand being 
omitted. No ADP peak is seen due to the presence of pyruvate kinase and 
phosphoenolpyruvate in the medium, (b) HPLC chromatogram showing adenosine, AMP, 
ADP and ATP standards at a concentration of 2 pM.
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5.4 Discussion
These results show that ATPaS binds to intact platelets in a reversible and saturable 
manner. Scatchard plots of homologous ATPaS displacement isotherms were non-linear 
and analysis of these data showed two binding sites, a high affinity binding site with a 
dissociation constant of 0.21 pM and a low affinity binding site with a dissociation 
constant of 32 pM. Of these two binding sites the high affinity binding site is most likely 
to represent an ADP receptor as the affinity of the low affinity site for ATPaS is too low 
in comparison with that obtained from functional studies which ranges between 1  and
4.6 pM (Cusack & Hourani, 1982b; Chapter 2 of this thesis). The affinity of ATPaS for 
the high affinity site is somewhat higher than that obtained in the functional studies, 
however, this may be due to more complete equilibration of the ligand with the receptors 
in these binding studies. In the experiments presented here the ATPaS was incubated 
with the platelets for 40 min to determine the binding constants whilst in the functional 
studies it was added simultaneously with agonist to avoid problems associated with its 
breakdown which would result in the formation of compounds with differing 
pharmacological properties. Thus in the functional studies the ligand may not have 
reached binding equilibrium with the receptor population (although Schild plots with unit 
slopes may suggest that it was) and this would result in an underestimation of the affinity 
of ATPaS for the receptor in the functional studies. There were -9000 high affinity sites 
per platelet when the presence of released ATP was taken into account and this number is 
somewhat greater than the 500 - 1200 MeSADP binding sites which have previously been 
reported (Macfarlane et al, 1983; Mills et a l, 1985; Cristalli & Mills, 1993). The number 
of low affinity binding sites, 24,148 =fc 9,988, is, however, comparable with the number of
144
high affinity ATPaS binding sites found on fixed platelets (31,000; Greco et a l , 1991) 
which appear to be associated with Gp Ilb-IIIa and indeed is within the range of the 
number of fibrinogen binding sites found on platelets (16,000 - 80,000; Siess, 1989).
The binding of ATPaS was not displaced by high concentrations of NECA (100 juM), 
yohimbine (10 pM) or ketanserin (1 pM) showing that it does not represent binding at 
adenosine, a 2  or 5-HT2  receptors. The binding was also not displaced by FSBA (100 pM) 
suggesting that neither of these binding sites represents 'aggregin' the 100 kDa membrane 
protein labelled by this compound (Colman, 1992). Also the binding was only weakly 
displaced by other naturally occurring nucleotides, the 46 % displacement achieved by 
100 pM GTP being similar in extent to that achieved by 100 pM AMPPCP or Ap5A 
(which had Kj values around 100 pM, see table 5.1) and suggesting therefore that GTP 
binds at least 300 fold less strongly than ATP to this binding site.
The high affinity binding of ATPaS to platelets was displaced by a number of ADP 
receptor antagonists. The correlations between the pK; values obtained in this study and 
the pAj values for these analogues in functional studies are shown in figure 5.7. The order 
of potency of the ATP analogues for the displacement of high affinity ATPaS binding 
was Cl-ATP > MeSATP = ATPaS « ATP > AMPCPP > AMPPCP « Ap5 A, which is most 
similar to the potency order of these analogues as antagonists of the inhibition by ADP of 
adenylate cyclase, which is Cl-ATP > ATPaS « ATP > Ap5A > AMPPCP (Cusack & 
Hourani, 1982b). Indeed a significant (p<0.05) correlation between the pK{ values for 
displacing ATPaS and the pA2  values for these analogues as inhibitors of the effects of 
ADP on adenylate cyclase was obtained. However, the slope obtained from regression 
analysis of these data was -2.5 suggesting that there is not a simple linear relationship
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Figure 5.7 Comparison of the abilities of a number ATP analogues to displace bound 
ATPaS from platelets and to inhibit responses to ADP. (a) Comparison with the 
published pAj values of these compounds against aggregation (Cusack & Hourani, 
1982b). (b) Comparison with the pA2  values of these compounds against increases in 
[Ca2+];. (c) Comparison with the published values of these compounds against 
inhibition of adenylate cyclase (Cusack & Hourani, 1982b). The lines show the least 
squares regression fit to the data points. Compounds were: ATP (•), ATPaS (■), Cl-ATP 
(A), Ap5A (♦) and AMPPCP (▼). For abbreviations, see text.
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between these parameters. The correlation between these pKj values and the pA, values 
for inhibition of aggregation and increases in cytosolic calcium concentration was not 
significant. The ability of MeSATP to displace this ATPaS binding is indicative of a 
competitive interaction by MeSATP at this ATPaS binding site. Interestingly, whilst 
MeSATP and its analogues appear to act as non-competitive antagonists of ADP-induced 
aggregation (Cusack & Hourani, 1982a) and increases in cytosolic calcium concentration 
(Chapter 2 of this thesis), MeSAMPPCP appears to be a competitive antagonist of the 
effects of ADP on adenylate cyclase (Hourani et al., 1986) again showing the 
structure-activity relationship of this binding to be more similar to that of inhibition of 
adenylate cyclase by ADP. The similar affinity of ATP and ATPaS for the high affinity 
binding site is consistent with the effect of these compounds on the binding of MeSADP 
to platelets (Cristalli & Mills, 1993). However, the affinities of these compounds 
obtained in the present study are somewhat higher than those found by Cristalli & Mills 
(1993), in that ATP and ATPaS displaced MeSADP with K; values of around 4 pM 
whilst in the present study the Kj values were 0.34 and 0.21 pM, respectively. This 
discrepancy may again be due to the rather longer incubation times used in the present 
study compared to that used in the MeSADP binding studies (40 min compared to 5 - 10 
min). However, along with the rather larger number of high affinity ATPaS binding sites 
this discrepancy between the affinities of ATP and ATPaS at these two binding sites may 
imply that they are in fact distinct sites. Of course it is possible that in the studies on 
MeSADP binding, which were performed in plasma or in buffer in the presence of 
EDTA, there was also some ADP released by the platelets and this may have affected the 
binding constants determined in this study. However, saturation protocols were used to 
determine the binding constants in the MeSADP binding studies, and so the added
MeSADP would have been able to compete with any released ADP and would therefore 
still have saturated the entire receptor population at a sufficiently high concentration. The 
determination of the receptor density should not, therefore, have been affected. As the 
effects of the other antagonists used in this study have not been determined on the 
binding of MeSADP to platelets it is not possible to compare these binding sites further.
The number of low affinity ATPaS binding sites is similar to the number of Gp Ilb-IIIa 
complexes on platelets (see Siess, 1989) and is also similar to the number of high affinity 
ATPaS (and ADP) binding sites found on fixed platelets (Jefferson et a l , 1988; Agarwal 
et a l , 1989; Greco et a l, 1991). However, where K; values could be determined in the 
present study they are generally higher (i.e. the compounds have lower affinity) than 
those found in the studies on fixed platelets and the potency order of these compounds 
are different. Whilst on fixed platelets the potency order is ATPaS > ATP > Cl-ATP, that 
obtained at the low affinity site in the present study is Cl-ATP > ATPaS > ATP. Whilst it 
is possible that these differences may suggest that these are also distinct binding sites and 
that the low affinity site described here is in fact not the binding site present on Gp 
Ilb-IIIa, it may also reflect changes in the structure of this binding site which may occur 
during the fixation process.
Suramin did not appear to displace ATPaS from the low affinity binding site and the 
displacement curve for suramin was somewhat steeper than that of the other compounds 
used in this study. This steep displacement curve may suggest a degree of positive 
cooperativity in the interaction of suramin with this binding site. This could explain the 
observed steep Schild plots for the inhibition by suramin of ADP-induced aggregation 
and increases in cytosolic calcium concentration as more than one molecule of suramin
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would have to bind to the ADP receptor in order for a cooperative interaction to be 
observed and this is indeed one explanation for a non-unit Schild plot slope. However, the 
slope of the Schild plot for inhibition by suramin of the effects of ADP on adenylate 
cyclase was not significantly different from unity suggesting a simple competitive 
interaction. This could be interpreted as showing that aggregation and inhibition of 
adenylate cyclase are indeed mediated by two distinct ADP receptors at which suramin 
displays a different binding interaction and that this ATPaS binding site represents an 
ADP receptor which induces increases in cytosolic calcium concentration and 
aggregation. However, the potency order for displacement by the ATP analogues was 
more similar to that for ADP-induced inhibition of adenylate cyclase than the other 
responses suggesting that this interpretation is not correct.
The affinities of ATP, Cl-ATP and AMPCPP (as well as that of ATPaS) are somewhat 
greater than those reported from functional studies (Macfarlane & Mills, 1975; Cusack & 
Hourani, 1982b; Lips et a l, 1980; Chapter 2 of this thesis). However, as for ATPaS this 
may be due to the rather longer incubation times used in the binding assays, 40 min 
compared to up to 1 min in the functional studies. In the case of AMPPCP and Ap5 A, the 
Kj values were rather greater than expected being approximately 100 juM for both 
compounds. From functional studies Ap5A would be expected to be equipotent with or 
slightly less potent than ATP and AMPPCP should be if anything slightly more potent 
than AMPCPP. The relatively low affinity and similar K; values for these compounds may 
suggest that they were perhaps being broken down during the assay to a compound which 
has veiy little affinity for the ADP receptor. However, at 100 jliM  none of the nucleotides 
used in this study showed any evidence of being broken down, thus breakdown cannot
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explain the results obtained with AMPPCP and Ap5 A. The most likely explanation for 
these discrepancies would be that the ATPaS is binding to a binding site distinct from the 
ADP receptor. The inability of NECA and FSBA to displace this binding is good evidence 
that this site does not represent an adenosine receptor or 'aggregin'. A possible candidate 
could be nucleoside diphosphokinase (NDPK). This enzyme does show a similar 
preference for the naturally occurring nucleotide triphosphates as substrates as the 
ATPaS binding site described here does for the displacement of bound ATPaS i.e. 
ATP > GTP > CTP (Packham et al., 1974). However, the structure-activity relationships 
of this enzyme for the ATP analogues described here are not known and would have to be 
determined before this binding site could be confirmed as NDPK.
These results, therefore, show that ATPaS binds to two binding sites on intact washed 
platelets, however, neither of these binding sites has properties which are entirely 
consistent with those of the ADP receptor. The low affinity site does not bind the ATP 
analogues studies with great enough affinity to represent the ADP receptor and is not 
displaced by suramin, whilst at the high affinity site the structure-activity relationship is 
not really consistent with the functional studies on the ADP receptor.
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CHAPTER 6 
GENERAL DISCUSSION
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This study has used a number of measures of platelet activation to investigate further the 
pharmacology of the human platelet ADP receptor. Studies on the effects of a number of 
ADP and ATP analogues on ADP-induced increases in platelet cytosolic calcium 
concentration showed that the structure-activity relationship of this response is very 
similar to that previously determined for these compounds on ADP-induced aggregation. 
This close correlation was further demonstrated in the studies on suramin, a compound 
which is structurally unrelated to ADP, which also showed very similar effects on these 
two responses to ADP. These observations provide further evidence in support of the 
view that this increase in platelet cytosolic calcium concentration is the major signal for 
platelet aggregation induced by this agonist. These results also cast further doubt on the 
use of the affinity reagent FSBA as a label of a platelet ADP receptor. FSBA has been 
shown to inhibit shape change and aggregation induced by ADP, but not to inhibit the 
effect of ADP on stimulated adenylate cyclase and this has been taken to imply that shape 
change and aggregation are mediated by a receptor distinct from that which causes the 
inhibition of stimulated adenylate cyclase (e.g. see Colman, 1992). However, FSBA was 
also unable to inhibit increases in platelet cytosolic calcium concentration induced by 
ADP (Rao & Kowalski, 1987) and this was taken by these authors to imply that increases 
in cytosolic calcium concentration induced by ADP may be induced by another receptor 
distinct from that inducing shape change and aggregation. This increase in cytosolic 
calcium concentration appears to be the major signal for aggregation induced by ADP 
and the studies presented here provide strong evidence that these two responses are 
mediated by the same receptor. Thus if FSBA does not inhibit the increase in cytosolic 
calcium concentration induced by ADP it cannot be acting at the ADP receptor and must 
therefore inhibit ADP-induced aggregation and shape change by a different mechanism.
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Another piece of evidence which has been taken to support the 'two receptor hypothesis' 
was the observation that the non-penetrating sulphydryl reagent pMBS inhibits the effects 
of ADP on stimulated adenylate cyclase but does not inhibit platelet shape change 
induced by this agonist (Mills & Macfarlane, 1977; Macfarlane & Mills, 1981). However, 
in the study by Rao & Kowalski (1987) these authors showed that whilst pMBS did not 
inhibit shape change induced by ADP it was able to inhibit increases in cytosolic calcium 
concentration induced by this compound, although this inhibition did not reach 1 0 0  % at 
the highest concentration of pMBS used (1 mM). In this study 1 mM pMBS inhibited 
-90 % of the increase in intracellular calcium induced by 25 juM ADP. However, platelet 
shape change is the most sensitive response of platelets to the presence of ADP 
suggesting that only a small increase in platelet cytosolic calcium concentration is 
required to induce this response (see figure 6.1). Thus, the lack of effect of pMBS on 
platelet shape change may simply reflect the fact that in the presence of 1 mM pMBS the 
increase in cytosolic calcium concentration induced by ADP is still sufficient to induce 
an unaltered shape change. It is also possible that pMBS could inhibit the increase in 
platelet cytosolic calcium concentration by modifying a membrane protein other than the 
ADP receptor, for example the store regulated calcium channel (Sage et a l, 1990) in 
which case it would not affect ADP-induced mobilization of calcium from intracellular 
stores. The shape change induced by ADP in EDTA-anticoagulated plasma, which was 
used in the study by Rao & Kowalski, is only dependent on this mobilization of calcium 
from intracellular stores and would therefore not be affected by agents which only inhibit 
the influx of extracellular calcium.
The correlation between the effects of the ADP and ATP analogues on increases in 
cytosolic calcium concentration and inhibition of adenylate cyclase was less good,
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however. As with aggregation the effects of the four ADP analogues tested here on 
increases in cytosolic calcium concentration were not in good agreement with their 
effects on adenylate cyclase. However, as with the discrepancy between the effects of 
these compounds on aggregation and adenylate cyclase, this is explicable in terms of 
differences in the efficacies of these compounds at the same receptor for inducing 
responses via different effector mechanisms rather than in terms of two receptors 
mediating the two responses (e.g. Hourani & Cusack, 1991). When the pA2  values for the 
antagonists which appeared to act competitively in this study were compared to those 
obtained for their inhibition of the effect of ADP on adenylate cyclase the correlation did 
not reach significance at the 5 % level, possibly suggesting that these two effects of ADP 
are indeed mediated by separate receptors. However, in my study only 5 compounds were 
used to make this comparison compared to the 8  compounds used by Cusack & Hourani 
(1982b) to compare the inhibition by ATP analogues of aggregation and the effect of 
ADP on adenylate cyclase. Indeed, if the same 5 compounds were used to make the 
comparison between aggregation and effects on adenylate cyclase this too is not 
significant at the 5 % level. Thus the effects of a larger number of antagonists need to be 
studied before the significance of this correlation can be properly evaluated.
The P2-purinoceptor antagonist suramin was also shown to inhibit platelet responses to 
ADP and the pA  ^ values obtained against each response was similar providing further 
evidence in favour of the hypothesis that only a single class of ADP receptor mediates 
increases in cytosolic calcium, aggregation and inhibition of adenylate cyclase. The pA2  
values obtained for suramin in this study were also similar to those obtained for the 
inhibition by suramin of responses to ATP mediated by other P2-purinoceptors (Hoyle et 
al, 1990; Inoue et a l, 1991; Leff et a l, 1990; Von Kiigelgen et a l, 1990) showing that
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suramin cannot distinguish between the various subtypes of P2 -purinoceptor. In the cases 
of aggregation and increases in platelet cytosolic calcium concentration this inhibition by 
suramin was not simply competitive, however, as the slope of the Schild plot was 
significantly greater than unity. Suramin was also able to inhibit non-competitively 
aggregation induced by U46619 and by 5-HT (in the presence of adrenaline) and 
increases in platelet cytosolic calcium concentration induced by 5-HT showing that 
suramin also has non-specific effects on these two platelet responses. As suramin is a 
highly charged molecule which does not cross the plasma membrane (Fortes et al., 1973) 
this non-specific effect is likely to occur at the cell surface and could be due to inhibition 
of the ion-channels involved in calcium influx. A non-specific effect of suramin on 
platelet calcium influx pathways would explain both the steep Schild plots obtained for 
aggregation and increases in cytosolic calcium and the unit Schild plot obtained for 
inhibition of the effect of ADP on adenylate cyclase. If suramin were blocking the influx 
of extracellular calcium as well as having a competitive inhibitory effect at the ADP 
receptor this would steepen the slope of the Schild plot for inhibition of aggregation and 
increases in cytosolic calcium concentration, as these responses are dependent on this 
influx of calcium. However, it would not affect the slope of the Schild plot for the 
inhibition of the effect of ADP on adenylate cyclase as this response is not dependent on 
an increase in intracellular calcium concentration (see Chapter 2). It might also be 
expected that such a non-competitive effect of suramin would decrease the maximal 
response to ADP, however this would depend on the relative ability of suramin to 
produce these inhibitory effects. The hypothesis that suramin is able to inhibit 
non-specifically agonist induced calcium influx could be tested by studying the effect of 
suramin on increases in platelet cytosolic calcium concentration in the absence of
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extracellular calcium. This would effectively negate the contribution to the inhibition that 
any effects of suramin on calcium influx may have by removing this influx.
Studies on the effects of varying the extracellular calcium concentration on platelet 
responses to ADP and their inhibition by ATP suggested that, in common with other 
P2-purinoceptors (Cockcroft & Gomperts, 1979; Fedan et a l, 1990; Motte et a l, 1993), 
the platelet ADP receptor is in fact a receptor for ADP3* and that the active antagonist is 
A tp4-. Thus it would appear that P2-purinoceptors possess a binding site for ATP4* rather 
than for Mg.ATP which is the ligand required by phosphotransferase enzymes. The 
magnesium ion seems to be required by the phosphotransferase enzymes to produce the 
correct conformation of the triphosphate chain for the phosphoryl transfer reaction to 
occur (Eckstein, 1985; Frey, 1992). Presumably therefore the purinoceptors require a 
conformation of the phosphate chain which is not accessible to the magnesium complex.
These results have important implications for the work in the rest of this thesis, 
particularly the work on ADP-induced increases in cytosolic calcium concentration and 
the binding studies and the comparison of these results with the results of previous 
studies. The various adenine nucleotide analogues used in these studies have different 
affinities for divalent cations than the parent nucleotide, for example AMPPCP has ~3 
fold greater affinity for magnesium than ATP (Yount et a l, 1971) whilst 
phosphorothioate analogues generally have lower affinities for magnesium than the 
parent nucleotide (Pecoraro et a l, 1984). Thus, in the presence of divalent cations the 
observed effects of these compounds will depend upon the stability constants of their 
divalent cation complexes as this will affect the concentration of the analogue present in 
the uncomplexed form. Consequently to gain a true comparison between the effects of
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these compounds on the various platelet responses to ADP it is necessary to measure the 
responses in the absence of divalent cations or at least to take into account their affinities 
for these cations. As platelet aggregation cannot be studied in the absence of divalent 
cations a knowledge of the relative affinities of the nucleotides studied for divalent 
cations would appear to be essential for a truly meaningful comparison of their effects to 
be made. Importantly, the studies on increases in intracellular calcium presented in this 
thesis were performed in the presence of 1 mM calcium and 1 mM magnesium, whilst the 
binding studies were performed in the absence of calcium. The absence of calcium will 
alter the observed affinity of these various compounds to different extents depending on 
their affinities for this metal ion. Similarly previous functional studies (e.g. Cusack & 
Hourani, 1981a, b; 1982a, b, c) were performed in citrated platelet-rich plasma, this not 
only contains enzymes capable of degrading adenine nucleotide analogues but also 
contains a lower concentration of divalent cations than that present in my studies on 
increases in cytosolic calcium concentration.
[3 5 S]-ATPaS was used as a radioligand in an attempt to determine the number and 
binding parameters of the platelet ADP receptor. Scatchard plots for this binding were 
non-linear and analysis of the data using the LIGAND program showed two classes of 
binding site. However, the neither of these binding sites had properties which were fully 
consistent with those of the ADP receptor determined in functional studies. In addition 
the release of adenine nucleotides by the platelets resulted in a marked underestimation 
of the number of high affinity binding sites for the radiolabel. Thus it would seem that 
washed platelets are not an ideal system for studying the binding of adenine nucleotides 
to platelets. However, it may be possible to improve this binding protocol (see below).
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6.1 Suggestions for Further Work
In light of the relatively poor correlation between the pA^ , values of ADP receptor 
antagonists on increases in intracellular calcium concentration and on inhibition of 
adenylate cyclase this is an obvious area for further study. This could be done either by 
determining the effects of a greater number of antagonists as used in the study by Cusack 
& Hourani (1982b) on increases in cytosolic calcium concentration or by determining the 
effects of AMPCPP and ATPpS on inhibition of adenylate cyclase. The compounds 
which were used in the study of Cusack & Hourani which were not used in the studies 
presented here were Rp-ATPaS, 2-chloroadenosine 5'-phosphorothioate and adenosine 
5'-0-(3-fluorotriphosphate). As these three compounds are not commercially available 
and cannot be synthesized enzymatically the most convenient approach would probably 
be to study the effects of ATPJ3S and AMPCPP on inhibition of adenylate cyclase.
From the studies of Sage & co-workers on the kinetics of increases in cytosolic calcium 
induced by ADP (see section 1.4.2 of the General Introduction) and from my work on 
suramin (see Chapter 3) it is possible that there are two ADP receptors mediating 
increases in platelet cytosolic calcium concentration, a ligand-gated ion-channel 
mediating influx and a G-protein coupled receptor causing the release of calcium from 
intracellular stores. It would therefore be interesting to study the structure-activity 
relationships associated with increases in platelet cytosolic calcium concentration in the 
absence of extracellular calcium. This would allow the mobilization of intracellular 
calcium to be studied in the absence of influx, and would allow further studies into the 
effects of extracellular divalent cations on responses to ADP. It would also be interesting 
determine the effects of pMBS on the response to ADP under these conditions to see if
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this compound does show selective effects on calcium influx over the release of calcium 
from intracellular stores. It may be more difficult to study influx in the absence of release 
from intracellular stores, however, Sage and co-workers have shown that the initial influx 
of calcium induced by ADP is not inhibited by cAMP (Sage & Rink, 1987). It may 
therefore be possible to study this influx alone in the presence of PGEj or adenosine at 
concentrations which inhibit the increase in cytosolic calcium concentration in the 
presence of EGTA. As stated earlier in this thesis (see the Discussion of Chapter 3) 
studying the effects of MeSATP and ADPaS on these two components of the increase in 
cytosolic calcium concentration separately may also be able to shed light on their 
mechanisms of action.
It may also be possible to overcome some of the drawbacks of the binding studies 
described here if the binding were studied in plasma anticoagulated with EDTA as was 
done by Macfarlane et al (1982; 1983). The use of an antagonist ligand will remove the 
possible complicating effects (e.g. difficulty in estimating the extracellular space) 
associated with platelet shape change which will occur when ADP analogues are used as 
radioligands. In the presence of EDTA the concentration of magnesium is extremely low 
and is not sufficient for the activity of nucleotidases thus removing the problems 
associated with nucleotide metabolism. The removal of magnesium may also prevent the 
binding of the NDPK as this enzyme requires the magnesium complex of ATP as a 
substrate. Also, in the presence of EDTA glycoprotein Ilb-IIIa will be dissociated and the 
nucleotide binding site on this molecule may therefore not be accessible. Indeed in the 
presence of EDTA photolabelling of glycoprotein Ilb-IIIa by ATPaS was markedly 
reduced (Greco et a l , 1991). Finally, in the absence of divalent cations the adenine
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nucleotides will be present predominantly as the uncomplexed species which seems to be 
the form recognised by the ADP receptor. It would still of course be necessary to 
determine whether the platelets were releasing adenine nucleotides under these 
conditions.
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Figure 6.1 A comparison of the ability of ADP to induced shape change (•) (n = 3), 
increases in cytosolic calcium concentration (■) (n = 34) and aggregation (A) (n = 10) of 
washed human platelets. The data are presented as a percentage of the response to the 
highest concentration of ADP used (30 pM for shape change, 100 pM for increases in 
cytosolic calcium concentration and 300 pM for aggregation). Values are the mean of at 
least 3 separate determinations (see brackets) and vertical bars show the s.e. mean.
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